[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fC02g9RXc7yEitMIv9Zkef2wl2XNNmWa0opT_U-7MP_Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"The Hospital for Sick Children",[4],567,false,98,76,1722155,18,411,[14,17,19,22,25,27,30,33],{"name":15,"count":16},"Healthy",25,{"name":18,"count":11},"Pain",{"name":20,"count":21},"Cystic Fibrosis",16,{"name":23,"count":24},"Congenital Heart Disease",11,{"name":26,"count":24},"Cancer",{"name":28,"count":29},"Pregnancy",9,{"name":31,"count":32},"Juvenile Idiopathic Arthritis",8,{"name":34,"count":35},"Diabetes Mellitus, Type 1",7,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04333823","Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial","2024-05","Dapagliflozin 5mg",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT02840409","Vinblastine +\u002F- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","2024-07-31","Vinblastine",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05426252","Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia","2025-12-31","Abatacept",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06635720","REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)","2026-02-16","Prednisone",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06823154","The Implementation and Impact of an Allergy De-Labeling Program in the Emergency Department","2026-02-17","Amoxicillin",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT03118986","RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy","2026-03","Olanzapine",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05562310","Phenylalanine, Methionine and Histidine Requirements in TPN Fed Neonates","2026-09-02","Total parenteral nutrition (TPN). This is total nutrition provided by central vein.",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06935019","TRIAGE-GS: Towards Reducing Inefficiencies Affecting Genetics Encounters Through Genome Sequencing","2026-12","Genome sequencing pre-geneticist evaluation",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT02740868","Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease","2026-12-31","Xenon-129 and Perfluoropropane",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06069687","Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50","2027-03","MELPIDA",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,126,144,182,202,248,283,304,325,348,366,393,413,435,484,511,533,558,580,619,644,672,690,717,735,753,778,805,831,849,874,892,917,935,960,985,1003,1026,1050,1097,1145,1189,1225,1263,1287,1310,1328,1353,1375,1401,1419,1443,1466,1484,1507,1531,1549,1567,1595,1613,1639,1657,1675,1699,1717,1741,1759,1790,1808,1826,1844,1869,1887,1905,1929,1947,1971,1994,2018,2043,2067,2085,2109,2133,2151,2169,2187,2210,2236,2254,2280,2298,2320,2338,2361,2388,2410,2428,2446,2471,2492,2514,2537,2555,2573,2591,2617,2635,2661,2679,2711,2741,2765,2787,2811,2836,2862,2887,2911,2936,2959,2988,3006,3024,3042,3060,3078,3100,3128,3146,3170,3193,3217,3235,3253,3274,3298,3325,3343,3361,3383,3407,3430,3448,3475,3493,3518,3536,3561,3579,3605,3628,3649,3672,3690,3713,3738,3762,3784,3808,3826,3849,3867,3893,3915,3939,3963,3988,4012,4036,4054,4077,4101,4126,4172,4212,4239,4265,4288,4312,4338,4361,4384,4407,4425,4451,4469,4487,4505,4528,4553,4576,4599,4623,4645],{"intervention":96,"totalTrials":97,"cells":98},"Bupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":124},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":122},"NCT04577690","PECS Study for CIED Implantation Surgery","RECRUITING",[92],"2028-01-01","2019-12-01",48,[119,120,121],"Pain, Postoperative","Child","Adolescent",[96,123],"Bupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only",{"trials":125,"activeCount":101},[],{"intervention":123,"totalTrials":97,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":142},{"trials":129,"activeCount":101},[],{"trials":131,"activeCount":101},[],{"trials":133,"activeCount":101},[],{"trials":135,"activeCount":101},[],{"trials":137,"activeCount":97,"soonestReadout":115},[138],{"nctId":111,"briefTitle":112,"status":113,"phases":139,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":140,"interventions":141},[92],[119,120,121],[96,123],{"trials":143,"activeCount":101},[],{"intervention":56,"totalTrials":145,"cells":146},2,{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":178,"NA":180},{"trials":148,"activeCount":101},[],{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":97,"soonestReadout":55},[155,167],{"nctId":53,"briefTitle":54,"status":156,"phases":157,"primaryCompletion":55,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":166},"ACTIVE_NOT_RECRUITING",[91],"2027-02-28","2024-11-01",50,[162,163,164,165],"Nephrotic Syndrome in Children","Nephrotic Syndrome, Minimal Change","Nephrotic Syndrome","Nephrotic Syndrome，Idiopathic",[56],{"nctId":168,"briefTitle":169,"status":170,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":9,"conditions":174,"interventions":176},"NCT03070522","Prednisone in Cystic Fibrosis Pulmonary Exacerbations","COMPLETED",[91],"2023-10-07","2017-05-01",[175],"Cystic Fibrosis Pulmonary Exacerbation",[56,177],"Placebos",{"trials":179,"activeCount":101},[],{"trials":181,"activeCount":101},[],{"intervention":41,"totalTrials":97,"cells":183},{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":198,"NA":200},{"trials":185,"activeCount":101},[],{"trials":187,"activeCount":101},[],{"trials":189,"activeCount":101},[],{"trials":191,"activeCount":97,"soonestReadout":40},[192],{"nctId":38,"briefTitle":39,"status":156,"phases":193,"primaryCompletion":40,"completion":40,"start":194,"enrollment":195,"conditions":196,"interventions":197},[91],"2020-12-11",100,[34],[41],{"trials":199,"activeCount":101},[],{"trials":201,"activeCount":101},[],{"intervention":203,"totalTrials":204,"cells":205},"Metformin",3,{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":232,"PHASE4":244,"NA":246},{"trials":207,"activeCount":101},[],{"trials":209,"activeCount":101},[],{"trials":211,"activeCount":97,"soonestReadout":85},[212,222],{"nctId":213,"briefTitle":214,"status":113,"phases":215,"primaryCompletion":85,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":221},"NCT04121468","A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis",[89,90],"2027-10","2020-02-24",20,[220],"Multiple Sclerosis (MS)",[203],{"nctId":223,"briefTitle":224,"status":170,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":29,"conditions":228,"interventions":230},"NCT00892073","Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy",[90],"2008-01","2006-05",[229],"Hypothalamic Obesity",[231,203],"Diazoxide",{"trials":233,"activeCount":101},[234],{"nctId":235,"briefTitle":236,"status":170,"phases":237,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},"NCT02040376","Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma",[91],"2017-12-15","2014-06-13",24,[242],"Brain Tumor Treated With Cranial or Cranial-Spinal Radiation",[203],{"trials":245,"activeCount":101},[],{"trials":247,"activeCount":101},[],{"intervention":66,"totalTrials":145,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":277,"PHASE4":279,"NA":281},{"trials":251,"activeCount":101},[],{"trials":253,"activeCount":101},[],{"trials":255,"activeCount":97,"soonestReadout":65},[256,266],{"nctId":257,"briefTitle":258,"status":170,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT02129478","Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study",[90],"2016-01","2014-03",15,[264],"Chemotherapy-induced Nausea and Vomiting",[66],{"nctId":63,"briefTitle":64,"status":113,"phases":267,"primaryCompletion":65,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":276},[90],"2026-04","2017-08-10",200,[272,273,274,275],"Vomiting in Infants and\u002For Children","Nausea","Hematopoietic System--Cancer","Oncology",[66],{"trials":278,"activeCount":101},[],{"trials":280,"activeCount":101},[],{"trials":282,"activeCount":101},[],{"intervention":81,"totalTrials":97,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":286,"activeCount":101},[],{"trials":288,"activeCount":101},[],{"trials":290,"activeCount":97,"soonestReadout":80},[291],{"nctId":78,"briefTitle":79,"status":113,"phases":292,"primaryCompletion":80,"completion":80,"start":293,"enrollment":294,"conditions":295,"interventions":297},[90],"2015-08",30,[20,296],"Asthma",[81],{"trials":299,"activeCount":101},[],{"trials":301,"activeCount":101},[],{"trials":303,"activeCount":101},[],{"intervention":51,"totalTrials":97,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":307,"activeCount":101},[],{"trials":309,"activeCount":101},[],{"trials":311,"activeCount":97,"soonestReadout":50},[312],{"nctId":48,"briefTitle":49,"status":113,"phases":313,"primaryCompletion":50,"completion":80,"start":314,"enrollment":218,"conditions":315,"interventions":317},[89,90],"2022-03-22",[316],"Thalassemia in Children",[51,318],"Sirolimus",{"trials":320,"activeCount":101},[],{"trials":322,"activeCount":101},[],{"trials":324,"activeCount":101},[],{"intervention":46,"totalTrials":97,"cells":326},{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":342,"PHASE4":344,"NA":346},{"trials":328,"activeCount":101},[],{"trials":330,"activeCount":101},[],{"trials":332,"activeCount":97,"soonestReadout":45},[333],{"nctId":43,"briefTitle":44,"status":156,"phases":334,"primaryCompletion":45,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},[90],"2026-08","2016-08-01",109,[339],"Low Grade Glioma",[46,341],"Bevacizumab",{"trials":343,"activeCount":101},[],{"trials":345,"activeCount":101},[],{"trials":347,"activeCount":101},[],{"intervention":341,"totalTrials":97,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":351,"activeCount":101},[],{"trials":353,"activeCount":101},[],{"trials":355,"activeCount":97,"soonestReadout":45},[356],{"nctId":43,"briefTitle":44,"status":156,"phases":357,"primaryCompletion":45,"completion":335,"start":336,"enrollment":337,"conditions":358,"interventions":359},[90],[339],[46,341],{"trials":361,"activeCount":101},[],{"trials":363,"activeCount":101},[],{"trials":365,"activeCount":101},[],{"intervention":318,"totalTrials":145,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":369,"activeCount":101},[],{"trials":371,"activeCount":101},[],{"trials":373,"activeCount":97,"soonestReadout":50},[374],{"nctId":48,"briefTitle":49,"status":113,"phases":375,"primaryCompletion":50,"completion":80,"start":314,"enrollment":218,"conditions":376,"interventions":377},[89,90],[316],[51,318],{"trials":379,"activeCount":101},[],{"trials":381,"activeCount":101},[],{"trials":383,"activeCount":101},[384],{"nctId":385,"briefTitle":386,"status":170,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":97,"conditions":390,"interventions":392},"NCT04707209","Sirolimus for Retinal Astrocytic Hamartoma",[93],"2024-03-22","2020-11-04",[391],"Retinal Astrocytic Hamartoma",[318],{"intervention":86,"totalTrials":97,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":396,"activeCount":101},[],{"trials":398,"activeCount":97,"soonestReadout":85},[399],{"nctId":83,"briefTitle":84,"status":156,"phases":400,"primaryCompletion":85,"completion":85,"start":401,"enrollment":97,"conditions":402,"interventions":404},[89],"2022-03-11",[403],"Spastic Paraplegia Type 50",[86],{"trials":406,"activeCount":101},[],{"trials":408,"activeCount":101},[],{"trials":410,"activeCount":101},[],{"trials":412,"activeCount":101},[],{"intervention":61,"totalTrials":97,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":416,"activeCount":101},[],{"trials":418,"activeCount":97,"soonestReadout":60},[419],{"nctId":58,"briefTitle":59,"status":156,"phases":420,"primaryCompletion":60,"completion":80,"start":421,"enrollment":422,"conditions":423,"interventions":426},[89],"2023-11-27",500,[424,425],"Allergy Amoxicillin","Beta-lactam Allergy Labels",[61],{"trials":428,"activeCount":101},[],{"trials":430,"activeCount":101},[],{"trials":432,"activeCount":101},[],{"trials":434,"activeCount":101},[],{"intervention":436,"totalTrials":204,"cells":437},"Dexamethasone",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":468,"NA":470},{"trials":439,"activeCount":101},[],{"trials":441,"activeCount":101},[],{"trials":443,"activeCount":101},[],{"trials":445,"activeCount":101},[446,457],{"nctId":447,"briefTitle":448,"status":170,"phases":449,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT00213226","Single Dose Versus Multiple Doses of Dexamethasone in Children With Acute Bronchiolitis",[91],"2006-04","2001-12",120,[454],"Bronchiolitis",[456],"dexamethasone",{"nctId":458,"briefTitle":459,"status":170,"phases":460,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT05638087","Dexamethasone Treatment for OSA in Children",[91],"2024-07-21","2025-12-30","2022-10-26",10,[466],"Obstructive Sleep Apnea",[436],{"trials":469,"activeCount":101},[],{"trials":471,"activeCount":97,"soonestReadout":476},[472],{"nctId":473,"briefTitle":474,"status":113,"phases":475,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":483},"NCT04559425","Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block",[],"2027-12-31","2029-12-31","2020-01-01",350,[481,482],"Heart Block Complete","Heart Block Second Degree",[436],{"intervention":485,"totalTrials":97,"cells":486},"Total parenteral nutrition (TPN): this is total nutrition provided by central vein.",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":488,"activeCount":101},[],{"trials":490,"activeCount":101},[],{"trials":492,"activeCount":101},[],{"trials":494,"activeCount":101},[],{"trials":496,"activeCount":101},[],{"trials":498,"activeCount":97,"soonestReadout":503},[499],{"nctId":500,"briefTitle":501,"status":113,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":510},"NCT06372314","Isoleucine, Leucine, Valine and Tryptophan Requirements in TPN Fed Neonates",[93],"2027-12","2026-01-01",80,[507,508,509],"Neonates on TPN","Stable Neonates","Neonates Managed in the ICU",[485],{"intervention":76,"totalTrials":97,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":514,"activeCount":101},[],{"trials":516,"activeCount":101},[],{"trials":518,"activeCount":101},[],{"trials":520,"activeCount":101},[],{"trials":522,"activeCount":101},[],{"trials":524,"activeCount":97,"soonestReadout":75},[525],{"nctId":73,"briefTitle":74,"status":526,"phases":527,"primaryCompletion":75,"completion":528,"start":529,"enrollment":270,"conditions":530,"interventions":532},"ENROLLING_BY_INVITATION",[93],"2028-05","2025-05-14",[531],"Genetic Conditions",[76],{"intervention":534,"totalTrials":97,"cells":535},"Dexamethasone 0.3mg\u002Fkg",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":546},{"trials":537,"activeCount":101},[],{"trials":539,"activeCount":101},[],{"trials":541,"activeCount":101},[],{"trials":543,"activeCount":101},[],{"trials":545,"activeCount":101},[],{"trials":547,"activeCount":97,"soonestReadout":553},[548],{"nctId":549,"briefTitle":550,"status":551,"phases":552,"primaryCompletion":553,"completion":476,"start":554,"enrollment":294,"conditions":555,"interventions":557},"NCT07345819","Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis","NOT_YET_RECRUITING",[93],"2027-09-30","2026-04-01",[556],"Orbital Cellulitis",[534],{"intervention":71,"totalTrials":97,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":561,"activeCount":101},[],{"trials":563,"activeCount":101},[],{"trials":565,"activeCount":101},[],{"trials":567,"activeCount":101},[],{"trials":569,"activeCount":101},[],{"trials":571,"activeCount":97,"soonestReadout":70},[572],{"nctId":68,"briefTitle":69,"status":113,"phases":573,"primaryCompletion":70,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},[93],"2027-09-02","2023-04-02",60,[508,578],"Receiving Total Parenteral Nutrition (TPN)",[71],{"intervention":581,"totalTrials":145,"cells":582},"0.9% NaCl",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":600,"PHASE4":602,"NA":617},{"trials":584,"activeCount":101},[],{"trials":586,"activeCount":101},[],{"trials":588,"activeCount":101},[589],{"nctId":590,"briefTitle":591,"status":592,"phases":593,"primaryCompletion":594,"completion":594,"start":595,"enrollment":262,"conditions":596,"interventions":598},"NCT01668277","Effects of Saline on Circulation in Children","TERMINATED",[90],"2014-12","2012-08",[597],"Pulmonary Hypertensive Crisis",[599,581],"7.2% NaCl",{"trials":601,"activeCount":101},[],{"trials":603,"activeCount":101},[604],{"nctId":605,"briefTitle":606,"status":607,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":615},"NCT02299063","Dexmedetomidine Effect on Mitochondrial Function","UNKNOWN",[92],"2019-12","2014-11",36,[613,614],"Complication of Anesthesia","Ischaemia-reperfusion Injury",[616,581],"Dexmedetomidine",{"trials":618,"activeCount":101},[],{"intervention":620,"totalTrials":97,"cells":621},"Recombinant Factor VIII",{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":642},{"trials":623,"activeCount":101},[],{"trials":625,"activeCount":101},[],{"trials":627,"activeCount":101},[],{"trials":629,"activeCount":101},[],{"trials":631,"activeCount":101},[632],{"nctId":633,"briefTitle":634,"status":170,"phases":635,"primaryCompletion":636,"completion":594,"start":637,"enrollment":638,"conditions":639,"interventions":641},"NCT01085344","Canadian Hemophilia Prophylaxis Study",[92],"2012-12","1997-06-26",56,[640],"Severe Hemophilia A",[620,620],{"trials":643,"activeCount":101},[],{"intervention":645,"totalTrials":97,"cells":646},"Pregvit®",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":670},{"trials":648,"activeCount":101},[],{"trials":650,"activeCount":101},[],{"trials":652,"activeCount":101},[],{"trials":654,"activeCount":101},[],{"trials":656,"activeCount":101},[657],{"nctId":658,"briefTitle":659,"status":170,"phases":660,"primaryCompletion":661,"completion":226,"start":662,"enrollment":663,"conditions":664,"interventions":668},"NCT02300155","Improving Multivitamin Supplementation to Pregnant Women",[92],"2006-10","2004-10",1370,[28,665,273,666,667],"Morning Sickness","Vomiting","Hyperemesis Gravidarum",[645,669],"Orifer F®",{"trials":671,"activeCount":101},[],{"intervention":669,"totalTrials":97,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":682,"NA":688},{"trials":675,"activeCount":101},[],{"trials":677,"activeCount":101},[],{"trials":679,"activeCount":101},[],{"trials":681,"activeCount":101},[],{"trials":683,"activeCount":101},[684],{"nctId":658,"briefTitle":659,"status":170,"phases":685,"primaryCompletion":661,"completion":226,"start":662,"enrollment":663,"conditions":686,"interventions":687},[92],[28,665,273,666,667],[645,669],{"trials":689,"activeCount":101},[],{"intervention":691,"totalTrials":97,"cells":692},"Standard IV rehydration",{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":715},{"trials":694,"activeCount":101},[],{"trials":696,"activeCount":101},[],{"trials":698,"activeCount":101},[],{"trials":700,"activeCount":101},[],{"trials":702,"activeCount":101},[703],{"nctId":704,"briefTitle":705,"status":170,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":713},"NCT00392145","Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis",[92],"2010-05","2006-11",226,[711,712],"Gastroenteritis","Dehydration",[691,714],"Rapid intravenous rehydration",{"trials":716,"activeCount":101},[],{"intervention":714,"totalTrials":97,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":733},{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":101},[],{"trials":724,"activeCount":101},[],{"trials":726,"activeCount":101},[],{"trials":728,"activeCount":101},[729],{"nctId":704,"briefTitle":705,"status":170,"phases":730,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":731,"interventions":732},[92],[711,712],[691,714],{"trials":734,"activeCount":101},[],{"intervention":616,"totalTrials":97,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":751},{"trials":738,"activeCount":101},[],{"trials":740,"activeCount":101},[],{"trials":742,"activeCount":101},[],{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":101},[747],{"nctId":605,"briefTitle":606,"status":607,"phases":748,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":749,"interventions":750},[92],[613,614],[616,581],{"trials":752,"activeCount":101},[],{"intervention":754,"totalTrials":97,"cells":755},"Medical Air vs Oxygen",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":776},{"trials":757,"activeCount":101},[],{"trials":759,"activeCount":101},[],{"trials":761,"activeCount":101},[],{"trials":763,"activeCount":101},[],{"trials":765,"activeCount":101},[766],{"nctId":767,"briefTitle":768,"status":170,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":29,"conditions":772,"interventions":775},"NCT03031626","Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome",[92],"2025-03-15","2016-09-01",[773,774],"Sleep Apnea, Central","Prader-Willi Syndrome",[754],{"trials":777,"activeCount":101},[],{"intervention":779,"totalTrials":97,"cells":780},"Quadravalent human papillomavirus vaccine",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":803},{"trials":782,"activeCount":101},[],{"trials":784,"activeCount":101},[],{"trials":786,"activeCount":101},[],{"trials":788,"activeCount":101},[],{"trials":790,"activeCount":101},[791],{"nctId":792,"briefTitle":793,"status":170,"phases":794,"primaryCompletion":795,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":802},"NCT02624349","Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients",[92],"2017-12","2013-10",37,[799,800,801],"Late Complication From Kidney Transplant","Complication of Transplanted Liver","Human Papillomavirus-Related Carcinoma",[779],{"trials":804,"activeCount":101},[],{"intervention":806,"totalTrials":97,"cells":807},"PregVit® contains 1.1 mg of folic acid",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":816,"NA":829},{"trials":809,"activeCount":101},[],{"trials":811,"activeCount":101},[],{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":101},[],{"trials":817,"activeCount":101},[818],{"nctId":819,"briefTitle":820,"status":170,"phases":821,"primaryCompletion":822,"completion":823,"start":824,"enrollment":825,"conditions":826,"interventions":827},"NCT02300948","Optimizing Periconceptional and Prenatal Folic Acid Supplementation",[92],"2013-02","2013-04","2006-12",83,[28],[806,828],"PregVit-folic 5® contains 5 mg of folic acid",{"trials":830,"activeCount":101},[],{"intervention":828,"totalTrials":97,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":847},{"trials":834,"activeCount":101},[],{"trials":836,"activeCount":101},[],{"trials":838,"activeCount":101},[],{"trials":840,"activeCount":101},[],{"trials":842,"activeCount":101},[843],{"nctId":819,"briefTitle":820,"status":170,"phases":844,"primaryCompletion":822,"completion":823,"start":824,"enrollment":825,"conditions":845,"interventions":846},[92],[28],[806,828],{"trials":848,"activeCount":101},[],{"intervention":850,"totalTrials":97,"cells":851},"Pentacel",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":860,"NA":872},{"trials":853,"activeCount":101},[],{"trials":855,"activeCount":101},[],{"trials":857,"activeCount":101},[],{"trials":859,"activeCount":101},[],{"trials":861,"activeCount":101},[862],{"nctId":863,"briefTitle":864,"status":170,"phases":865,"primaryCompletion":866,"completion":867,"start":868,"enrollment":452,"conditions":869,"interventions":870},"NCT00390130","Does the Order in Which Vaccines Are Administered Affect Pain Response?",[92],"2007-06","2008-07","2006-07",[18],[850,871],"Prevnar",{"trials":873,"activeCount":101},[],{"intervention":871,"totalTrials":97,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":890},{"trials":877,"activeCount":101},[],{"trials":879,"activeCount":101},[],{"trials":881,"activeCount":101},[],{"trials":883,"activeCount":101},[],{"trials":885,"activeCount":101},[886],{"nctId":863,"briefTitle":864,"status":170,"phases":887,"primaryCompletion":866,"completion":867,"start":868,"enrollment":452,"conditions":888,"interventions":889},[92],[18],[850,871],{"trials":891,"activeCount":101},[],{"intervention":893,"totalTrials":97,"cells":894},"Ketamine",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":915},{"trials":896,"activeCount":101},[],{"trials":898,"activeCount":101},[],{"trials":900,"activeCount":101},[],{"trials":902,"activeCount":101},[],{"trials":904,"activeCount":101},[905],{"nctId":906,"briefTitle":907,"status":170,"phases":908,"primaryCompletion":909,"completion":909,"start":910,"enrollment":638,"conditions":911,"interventions":913},"NCT02295553","Ketamine and Propofol for Upper Endoscopy",[92],"2016-12","2013-07",[912],"Anesthesia",[893,914],"Propofol",{"trials":916,"activeCount":101},[],{"intervention":914,"totalTrials":97,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":933},{"trials":920,"activeCount":101},[],{"trials":922,"activeCount":101},[],{"trials":924,"activeCount":101},[],{"trials":926,"activeCount":101},[],{"trials":928,"activeCount":101},[929],{"nctId":906,"briefTitle":907,"status":170,"phases":930,"primaryCompletion":909,"completion":909,"start":910,"enrollment":638,"conditions":931,"interventions":932},[92],[912],[893,914],{"trials":934,"activeCount":101},[],{"intervention":936,"totalTrials":97,"cells":937},"Bicarbonate hemodialysis solution",{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":958},{"trials":939,"activeCount":101},[],{"trials":941,"activeCount":101},[],{"trials":943,"activeCount":101},[],{"trials":945,"activeCount":101},[],{"trials":947,"activeCount":101},[948],{"nctId":949,"briefTitle":950,"status":170,"phases":951,"primaryCompletion":952,"completion":594,"start":953,"enrollment":954,"conditions":955,"interventions":957},"NCT01930370","Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal",[92],"2014-07","2010-03",12,[956],"Chronic Dialysis Patients",[936,936],{"trials":959,"activeCount":101},[],{"intervention":961,"totalTrials":97,"cells":962},"PEG-Lyte®",{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":971,"NA":983},{"trials":964,"activeCount":101},[],{"trials":966,"activeCount":101},[],{"trials":968,"activeCount":101},[],{"trials":970,"activeCount":101},[],{"trials":972,"activeCount":101},[973],{"nctId":974,"briefTitle":975,"status":170,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":825,"conditions":979,"interventions":981},"NCT00380497","Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children",[92],"2007-09","2006-09",[980],"Colonoscopy",[961,982],"Pico-Salax®",{"trials":984,"activeCount":101},[],{"intervention":982,"totalTrials":97,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":1001},{"trials":988,"activeCount":101},[],{"trials":990,"activeCount":101},[],{"trials":992,"activeCount":101},[],{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":101},[997],{"nctId":974,"briefTitle":975,"status":170,"phases":998,"primaryCompletion":977,"completion":977,"start":978,"enrollment":825,"conditions":999,"interventions":1000},[92],[980],[961,982],{"trials":1002,"activeCount":101},[],{"intervention":1004,"totalTrials":97,"cells":1005},"rhDNAse",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1024},{"trials":1007,"activeCount":101},[],{"trials":1009,"activeCount":101},[],{"trials":1011,"activeCount":101},[],{"trials":1013,"activeCount":101},[],{"trials":1015,"activeCount":101},[1016],{"nctId":1017,"briefTitle":1018,"status":170,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":226,"enrollment":1021,"conditions":1022,"interventions":1023},"NCT00557089","The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis",[92],"2009-06",17,[20],[1004],{"trials":1025,"activeCount":101},[],{"intervention":1027,"totalTrials":97,"cells":1028},"DDAVP",{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1048},{"trials":1030,"activeCount":101},[],{"trials":1032,"activeCount":101},[],{"trials":1034,"activeCount":101},[],{"trials":1036,"activeCount":101},[],{"trials":1038,"activeCount":101},[1039],{"nctId":1040,"briefTitle":1041,"status":607,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":294,"conditions":1045,"interventions":1047},"NCT03136003","DDAVP vs. Exercise in Patients With Mild Hemophilia A",[92],"2018-08","2017-07-04",[1046],"Mild Haemophilia A Without Inhibitor",[1027],{"trials":1049,"activeCount":101},[],{"intervention":1051,"totalTrials":204,"cells":1052},"Lidocaine",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1093,"NA":1095},{"trials":1054,"activeCount":101},[],{"trials":1056,"activeCount":101},[],{"trials":1058,"activeCount":101},[],{"trials":1060,"activeCount":101},[1061,1071,1081],{"nctId":1062,"briefTitle":1063,"status":170,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1069},"NCT00519207","Evaluation of Topical Liposomal Lidocaine and Oral Sucrose for Treatment of Pain in Newborns Undergoing Venipuncture",[91],"2009-02","2007-08",330,[18],[1051,1070],"24% Sucrose Solution",{"nctId":1072,"briefTitle":1073,"status":170,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1080},"NCT02983682","Lidocaine Infusions for Chronic Pain in Children",[91],"2023-12","2017-01",19,[1079],"Pain, Chronic",[1051],{"nctId":1082,"briefTitle":1083,"status":607,"phases":1084,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT01503060","Effectiveness of Parent-Led Interventions in Reducing Infant Hypersensitivity to Pain",[91],"2016-04","2011-12",352,[18],[1090,1091,1092,1051],"Sucrose Placebo","Sucrose","Lidocaine Placebo",{"trials":1094,"activeCount":101},[],{"trials":1096,"activeCount":101},[],{"intervention":1098,"totalTrials":204,"cells":1099},"Prednisolone",{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1117,"PHASE4":1141,"NA":1143},{"trials":1101,"activeCount":101},[],{"trials":1103,"activeCount":101},[],{"trials":1105,"activeCount":101},[1106],{"nctId":1107,"briefTitle":1108,"status":170,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1115},"NCT00213252","Use of Montelukast to Treat Children With Mild to Moderate Acute Asthma",[90],"2008-02","2005-09",130,[1114],"Asthma, Bronchial",[1116,1098],"Montelukast plus prednisolone",{"trials":1118,"activeCount":101},[1119,1130],{"nctId":1120,"briefTitle":1121,"status":170,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":218,"conditions":1125,"interventions":1127},"NCT00312520","Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy",[91],"2005-06","2002-07",[1126],"Hemangiomas",[1128,1129],"prednisolone","methylprednisolone",{"nctId":1131,"briefTitle":1132,"status":1133,"phases":1134,"primaryCompletion":1135,"completion":1135,"start":1136,"enrollment":101,"conditions":1137,"interventions":1139},"NCT02299115","Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms","WITHDRAWN",[91],"2019-03-06","2017-09-05",[1138],"Infantile Spasms",[1098,1140],"Vigabatrin",{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":101},[],{"intervention":1146,"totalTrials":204,"cells":1147},"Gabapentin",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1161,"PHASE3":1163,"PHASE4":1185,"NA":1187},{"trials":1149,"activeCount":101},[],{"trials":1151,"activeCount":101},[1152],{"nctId":1153,"briefTitle":1154,"status":1133,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":101,"conditions":1158,"interventions":1160},"NCT01092520","Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children",[89],"2011-07","2009-07",[1159],"Pruritus",[1146],{"trials":1162,"activeCount":101},[],{"trials":1164,"activeCount":101},[1165,1174],{"nctId":1166,"briefTitle":1167,"status":170,"phases":1168,"primaryCompletion":707,"completion":1169,"start":450,"enrollment":1170,"conditions":1171,"interventions":1172},"NCT00312260","Comparing Gabapentin and Amitriptyline for the Treatment of Neuropathic Pain in Children and Adolescents",[91],"2017-03-02",34,[18],[1146,1173],"Amitriptyline",{"nctId":1175,"briefTitle":1176,"status":170,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1184},"NCT00684112","Analgesic Effects of Gabapentin After Scoliosis Surgery in Children",[91],"2009-12","2010-02","2008-05",35,[1183],"Scoliosis",[1146],{"trials":1186,"activeCount":101},[],{"trials":1188,"activeCount":101},[],{"intervention":1190,"totalTrials":145,"cells":1191},"Nadolol",{"EARLY_PHASE1":1192,"PHASE1":1194,"PHASE2":1196,"PHASE3":1208,"PHASE4":1221,"NA":1223},{"trials":1193,"activeCount":101},[],{"trials":1195,"activeCount":101},[],{"trials":1197,"activeCount":101},[1198],{"nctId":1199,"briefTitle":1200,"status":170,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":218,"conditions":1205,"interventions":1207},"NCT01010308","Nadolol for Proliferating Infantile Hemangiomas",[90],"2011-05","2012-02","2009-11",[1206],"Infantile Hemangioma",[1190],{"trials":1209,"activeCount":101},[1210],{"nctId":1211,"briefTitle":1212,"status":170,"phases":1213,"primaryCompletion":1214,"completion":1215,"start":1216,"enrollment":1217,"conditions":1218,"interventions":1219},"NCT02505971","Nadolol Versus Propranolol in Children With Infantile Hemangiomas",[91],"2020-04","2020-06-30","2015-09",74,[1206],[1190,1220],"Propranolol",{"trials":1222,"activeCount":101},[],{"trials":1224,"activeCount":101},[],{"intervention":1226,"totalTrials":145,"cells":1227},"Saline",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1259,"NA":1261},{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[],{"trials":1235,"activeCount":101},[1236,1248],{"nctId":1237,"briefTitle":1238,"status":592,"phases":1239,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1246},"NCT01576679","Safety and Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-Abdominal Collections in Children - A Prospective Study",[91],"2016-05","2017-06","2012-03",28,[1245],"Intra-abdominal Abscess",[1247,1226],"Cathflo",{"nctId":1249,"briefTitle":1250,"status":607,"phases":1251,"primaryCompletion":1252,"completion":1020,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1257},"NCT00618852","Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates",[91],"2008-12","2007-01",64,[1256],"Lung Disease",[1258,1226],"Furosemide",{"trials":1260,"activeCount":101},[],{"trials":1262,"activeCount":101},[],{"intervention":1264,"totalTrials":97,"cells":1265},"Antithrombin III",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1283,"NA":1285},{"trials":1267,"activeCount":101},[],{"trials":1269,"activeCount":101},[],{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[1274],{"nctId":1275,"briefTitle":1276,"status":170,"phases":1277,"primaryCompletion":1278,"completion":1278,"start":1279,"enrollment":11,"conditions":1280,"interventions":1282},"NCT01530737","Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery",[91],"2014-10","2011-11",[1281],"Cardiopulmonary Bypass",[1264],{"trials":1284,"activeCount":101},[],{"trials":1286,"activeCount":101},[],{"intervention":1288,"totalTrials":97,"cells":1289},"Fentanyl",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1296,"PHASE4":1306,"NA":1308},{"trials":1291,"activeCount":101},[],{"trials":1293,"activeCount":101},[],{"trials":1295,"activeCount":101},[],{"trials":1297,"activeCount":101},[1298],{"nctId":1299,"briefTitle":1300,"status":170,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":708,"enrollment":1254,"conditions":1303,"interventions":1304},"NCT00405444","Intranasal Fentanyl Versus Placebo for Catheterization During a Voiding Cystourethrogram in Children",[91],"2008-09",[18],[1288,1305],"Sterile water",{"trials":1307,"activeCount":101},[],{"trials":1309,"activeCount":101},[],{"intervention":1305,"totalTrials":97,"cells":1311},{"EARLY_PHASE1":1312,"PHASE1":1314,"PHASE2":1316,"PHASE3":1318,"PHASE4":1324,"NA":1326},{"trials":1313,"activeCount":101},[],{"trials":1315,"activeCount":101},[],{"trials":1317,"activeCount":101},[],{"trials":1319,"activeCount":101},[1320],{"nctId":1299,"briefTitle":1300,"status":170,"phases":1321,"primaryCompletion":1302,"completion":1302,"start":708,"enrollment":1254,"conditions":1322,"interventions":1323},[91],[18],[1288,1305],{"trials":1325,"activeCount":101},[],{"trials":1327,"activeCount":101},[],{"intervention":1329,"totalTrials":97,"cells":1330},"Brimonidine 0.33% gel",{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1349,"NA":1351},{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":101},[],{"trials":1336,"activeCount":101},[],{"trials":1338,"activeCount":101},[1339],{"nctId":1340,"briefTitle":1341,"status":592,"phases":1342,"primaryCompletion":1343,"completion":1343,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1348},"NCT02764411","Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations",[91],"2018-10","2016-06",6,[1347],"Capillary Malformations",[1329],{"trials":1350,"activeCount":101},[],{"trials":1352,"activeCount":101},[],{"intervention":1354,"totalTrials":97,"cells":1355},"Vitamin E",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1371,"NA":1373},{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"trials":1361,"activeCount":101},[],{"trials":1363,"activeCount":101},[1364],{"nctId":1365,"briefTitle":1366,"status":170,"phases":1367,"completion":1368,"start":1124,"enrollment":21,"conditions":1369,"interventions":1370},"NCT00311116","Vitamin E to Prevent Mucositis in Children With Cancer",[90,91],"2005-02",[26],[1354],{"trials":1372,"activeCount":101},[],{"trials":1374,"activeCount":101},[],{"intervention":1376,"totalTrials":97,"cells":1377},"7-valent pneumococcal conjugate vaccine",{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1397,"NA":1399},{"trials":1379,"activeCount":101},[],{"trials":1381,"activeCount":101},[],{"trials":1383,"activeCount":101},[],{"trials":1385,"activeCount":101},[1386],{"nctId":1387,"briefTitle":1388,"status":170,"phases":1389,"primaryCompletion":1390,"completion":1390,"start":1124,"enrollment":1391,"conditions":1392,"interventions":1395},"NCT00213265","Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants",[91],"2017-02",81,[1393,1394],"Organ Transplant","Immunosuppression",[1376,1396],"Pneumococcal 7-valent Conjugate Vaccine",{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"intervention":1396,"totalTrials":97,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1409,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":101},[],{"trials":1406,"activeCount":101},[],{"trials":1408,"activeCount":101},[],{"trials":1410,"activeCount":101},[1411],{"nctId":1387,"briefTitle":1388,"status":170,"phases":1412,"primaryCompletion":1390,"completion":1390,"start":1124,"enrollment":1391,"conditions":1413,"interventions":1414},[91],[1393,1394],[1376,1396],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"intervention":1420,"totalTrials":97,"cells":1421},"morphine, amethocaine",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1439,"NA":1441},{"trials":1423,"activeCount":101},[],{"trials":1425,"activeCount":101},[],{"trials":1427,"activeCount":101},[],{"trials":1429,"activeCount":101},[1430],{"nctId":1431,"briefTitle":1432,"status":170,"phases":1433,"completion":1123,"start":1434,"enrollment":1435,"conditions":1436,"interventions":1438},"NCT00213200","Intravenous and Topical Analgesics for Procedural Pain in Neonates",[91],"2003-07",108,[18,1437],"Infant, Newborn",[1420],{"trials":1440,"activeCount":101},[],{"trials":1442,"activeCount":101},[],{"intervention":1444,"totalTrials":97,"cells":1445},"Enoxaparin",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1462,"NA":1464},{"trials":1447,"activeCount":101},[],{"trials":1449,"activeCount":101},[],{"trials":1451,"activeCount":101},[],{"trials":1453,"activeCount":101},[1454],{"nctId":1455,"briefTitle":1456,"status":1133,"phases":1457,"primaryCompletion":293,"completion":293,"start":1458,"enrollment":101,"conditions":1459,"interventions":1461},"NCT01474902","Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery",[91],"2011-08",[1460],"Asymptotic Venous Thrombosis",[1444],{"trials":1463,"activeCount":101},[],{"trials":1465,"activeCount":101},[],{"intervention":1070,"totalTrials":97,"cells":1467},{"EARLY_PHASE1":1468,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1480,"NA":1482},{"trials":1469,"activeCount":101},[],{"trials":1471,"activeCount":101},[],{"trials":1473,"activeCount":101},[],{"trials":1475,"activeCount":101},[1476],{"nctId":1062,"briefTitle":1063,"status":170,"phases":1477,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1478,"interventions":1479},[91],[18],[1051,1070],{"trials":1481,"activeCount":101},[],{"trials":1483,"activeCount":101},[],{"intervention":1485,"totalTrials":97,"cells":1486},"intravenous metoclopramide",{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1491,"PHASE3":1493,"PHASE4":1503,"NA":1505},{"trials":1488,"activeCount":101},[],{"trials":1490,"activeCount":101},[],{"trials":1492,"activeCount":101},[],{"trials":1494,"activeCount":101},[1495],{"nctId":1496,"briefTitle":1497,"status":592,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":261,"enrollment":464,"conditions":1500,"interventions":1502},"NCT02098915","Metoclopramide Pilot Trial",[91],"2019-12-12",[1501],"Gastroschisis",[1485],{"trials":1504,"activeCount":101},[],{"trials":1506,"activeCount":101},[],{"intervention":1508,"totalTrials":97,"cells":1509},"Magnesium Sulfate",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1516,"PHASE4":1527,"NA":1529},{"trials":1511,"activeCount":101},[],{"trials":1513,"activeCount":101},[],{"trials":1515,"activeCount":101},[],{"trials":1517,"activeCount":101},[1518],{"nctId":1519,"briefTitle":1520,"status":170,"phases":1521,"primaryCompletion":1522,"completion":910,"start":450,"enrollment":452,"conditions":1523,"interventions":1525},"NCT00313963","MAST - Magnesium for Sickle Cell Acute Crisis in Children",[91],"2008-08",[1524],"Anemia, Sickle Cell",[1508,1526],"Normal Saline",{"trials":1528,"activeCount":101},[],{"trials":1530,"activeCount":101},[],{"intervention":1526,"totalTrials":97,"cells":1532},{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1539,"PHASE4":1545,"NA":1547},{"trials":1534,"activeCount":101},[],{"trials":1536,"activeCount":101},[],{"trials":1538,"activeCount":101},[],{"trials":1540,"activeCount":101},[1541],{"nctId":1519,"briefTitle":1520,"status":170,"phases":1542,"primaryCompletion":1522,"completion":910,"start":450,"enrollment":452,"conditions":1543,"interventions":1544},[91],[1524],[1508,1526],{"trials":1546,"activeCount":101},[],{"trials":1548,"activeCount":101},[],{"intervention":1173,"totalTrials":97,"cells":1550},{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1563,"NA":1565},{"trials":1552,"activeCount":101},[],{"trials":1554,"activeCount":101},[],{"trials":1556,"activeCount":101},[],{"trials":1558,"activeCount":101},[1559],{"nctId":1166,"briefTitle":1167,"status":170,"phases":1560,"primaryCompletion":707,"completion":1169,"start":450,"enrollment":1170,"conditions":1561,"interventions":1562},[91],[18],[1146,1173],{"trials":1564,"activeCount":101},[],{"trials":1566,"activeCount":101},[],{"intervention":1568,"totalTrials":97,"cells":1569},"Vitamin D - Cholecalciferol 400 IU",{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1591,"NA":1593},{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"trials":1575,"activeCount":101},[],{"trials":1577,"activeCount":101},[1578],{"nctId":1579,"briefTitle":1580,"status":170,"phases":1581,"primaryCompletion":1582,"completion":1583,"start":1584,"enrollment":1585,"conditions":1586,"interventions":1589},"NCT01419262","DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers",[91],"2015-05","2015-10","2011-09",703,[1587,296,1588],"Respiratory Tract Infections","Avitaminosis",[1568,1590],"Vitamin D3 - Cholecalciferol 2000 IU",{"trials":1592,"activeCount":101},[],{"trials":1594,"activeCount":101},[],{"intervention":1590,"totalTrials":97,"cells":1596},{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1603,"PHASE4":1609,"NA":1611},{"trials":1598,"activeCount":101},[],{"trials":1600,"activeCount":101},[],{"trials":1602,"activeCount":101},[],{"trials":1604,"activeCount":101},[1605],{"nctId":1579,"briefTitle":1580,"status":170,"phases":1606,"primaryCompletion":1582,"completion":1583,"start":1584,"enrollment":1585,"conditions":1607,"interventions":1608},[91],[1587,296,1588],[1568,1590],{"trials":1610,"activeCount":101},[],{"trials":1612,"activeCount":101},[],{"intervention":1614,"totalTrials":97,"cells":1615},"Ketorolac",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1635,"NA":1637},{"trials":1617,"activeCount":101},[],{"trials":1619,"activeCount":101},[],{"trials":1621,"activeCount":101},[],{"trials":1623,"activeCount":101},[1624],{"nctId":1625,"briefTitle":1626,"status":170,"phases":1627,"primaryCompletion":1628,"completion":1628,"start":227,"enrollment":1629,"conditions":1630,"interventions":1632},"NCT00405262","A Comparison of Bupivacaine and Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting",[91],"2008-10",54,[1631],"Postoperative Pain",[1614,1633,1634],"Bupivacaine","ketorolac + bupivacaine",{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":101},[],{"intervention":1633,"totalTrials":97,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1653,"NA":1655},{"trials":1642,"activeCount":101},[],{"trials":1644,"activeCount":101},[],{"trials":1646,"activeCount":101},[],{"trials":1648,"activeCount":101},[1649],{"nctId":1625,"briefTitle":1626,"status":170,"phases":1650,"primaryCompletion":1628,"completion":1628,"start":227,"enrollment":1629,"conditions":1651,"interventions":1652},[91],[1631],[1614,1633,1634],{"trials":1654,"activeCount":101},[],{"trials":1656,"activeCount":101},[],{"intervention":1634,"totalTrials":97,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1671,"NA":1673},{"trials":1660,"activeCount":101},[],{"trials":1662,"activeCount":101},[],{"trials":1664,"activeCount":101},[],{"trials":1666,"activeCount":101},[1667],{"nctId":1625,"briefTitle":1626,"status":170,"phases":1668,"primaryCompletion":1628,"completion":1628,"start":227,"enrollment":1629,"conditions":1669,"interventions":1670},[91],[1631],[1614,1633,1634],{"trials":1672,"activeCount":101},[],{"trials":1674,"activeCount":101},[],{"intervention":1676,"totalTrials":97,"cells":1677},"Desogestrel-Ethinyl Estradiol 21",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1695,"NA":1697},{"trials":1679,"activeCount":101},[],{"trials":1681,"activeCount":101},[],{"trials":1683,"activeCount":101},[],{"trials":1685,"activeCount":101},[1686],{"nctId":1687,"briefTitle":1688,"status":607,"phases":1689,"primaryCompletion":1180,"completion":1690,"start":227,"enrollment":1112,"conditions":1691,"interventions":1693},"NCT00326404","Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents",[91],"2009-05",[1692],"Contraception",[1676,1694],"Desogestrel-Ethinyl Estradiol 28",{"trials":1696,"activeCount":101},[],{"trials":1698,"activeCount":101},[],{"intervention":1694,"totalTrials":97,"cells":1700},{"EARLY_PHASE1":1701,"PHASE1":1703,"PHASE2":1705,"PHASE3":1707,"PHASE4":1713,"NA":1715},{"trials":1702,"activeCount":101},[],{"trials":1704,"activeCount":101},[],{"trials":1706,"activeCount":101},[],{"trials":1708,"activeCount":101},[1709],{"nctId":1687,"briefTitle":1688,"status":607,"phases":1710,"primaryCompletion":1180,"completion":1690,"start":227,"enrollment":1112,"conditions":1711,"interventions":1712},[91],[1692],[1676,1694],{"trials":1714,"activeCount":101},[],{"trials":1716,"activeCount":101},[],{"intervention":1718,"totalTrials":97,"cells":1719},"TPA",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1737,"NA":1739},{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[],{"trials":1727,"activeCount":101},[1728],{"nctId":1729,"briefTitle":1730,"status":170,"phases":1731,"primaryCompletion":795,"completion":795,"start":636,"enrollment":1732,"conditions":1733,"interventions":1735},"NCT01717742","Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)",[91],97,[1734],"Pleural Empyema",[1718,1736],"DNase",{"trials":1738,"activeCount":101},[],{"trials":1740,"activeCount":101},[],{"intervention":1736,"totalTrials":97,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1755,"NA":1757},{"trials":1744,"activeCount":101},[],{"trials":1746,"activeCount":101},[],{"trials":1748,"activeCount":101},[],{"trials":1750,"activeCount":101},[1751],{"nctId":1729,"briefTitle":1730,"status":170,"phases":1752,"primaryCompletion":795,"completion":795,"start":636,"enrollment":1732,"conditions":1753,"interventions":1754},[91],[1734],[1718,1736],{"trials":1756,"activeCount":101},[],{"trials":1758,"activeCount":101},[],{"intervention":1760,"totalTrials":97,"cells":1761},"Fast Release Melatonin",{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1786,"NA":1788},{"trials":1763,"activeCount":101},[],{"trials":1765,"activeCount":101},[],{"trials":1767,"activeCount":101},[],{"trials":1769,"activeCount":101},[1770],{"nctId":1771,"briefTitle":1772,"status":170,"phases":1773,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":1777,"conditions":1778,"interventions":1782},"NCT01161108","Trial of Melatonin to Improve Sleep in Children With Epilepsy and Neurodevelopmental Disabilities",[91],"2012-05","2012-06","2010-07",13,[1779,1780,1781],"Epilepsy","Insomnia","Developmental Disability",[1760,1783,1784,1785],"Fast Release Placebo","Timed Release Melatonin","Timed Release Placebo",{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":101},[],{"intervention":1783,"totalTrials":97,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1804,"NA":1806},{"trials":1793,"activeCount":101},[],{"trials":1795,"activeCount":101},[],{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[1800],{"nctId":1771,"briefTitle":1772,"status":170,"phases":1801,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":1777,"conditions":1802,"interventions":1803},[91],[1779,1780,1781],[1760,1783,1784,1785],{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":101},[],{"intervention":1784,"totalTrials":97,"cells":1809},{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1814,"PHASE3":1816,"PHASE4":1822,"NA":1824},{"trials":1811,"activeCount":101},[],{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":101},[1818],{"nctId":1771,"briefTitle":1772,"status":170,"phases":1819,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":1777,"conditions":1820,"interventions":1821},[91],[1779,1780,1781],[1760,1783,1784,1785],{"trials":1823,"activeCount":101},[],{"trials":1825,"activeCount":101},[],{"intervention":1785,"totalTrials":97,"cells":1827},{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1840,"NA":1842},{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[],{"trials":1833,"activeCount":101},[],{"trials":1835,"activeCount":101},[1836],{"nctId":1771,"briefTitle":1772,"status":170,"phases":1837,"primaryCompletion":1774,"completion":1775,"start":1776,"enrollment":1777,"conditions":1838,"interventions":1839},[91],[1779,1780,1781],[1760,1783,1784,1785],{"trials":1841,"activeCount":101},[],{"trials":1843,"activeCount":101},[],{"intervention":1845,"totalTrials":97,"cells":1846},"High dose dexamethasone",{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1853,"PHASE4":1865,"NA":1867},{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":101},[],{"trials":1852,"activeCount":101},[],{"trials":1854,"activeCount":101},[1855],{"nctId":1856,"briefTitle":1857,"status":592,"phases":1858,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":16,"conditions":1861,"interventions":1863},"NCT01135550","Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation",[91],"2013-12","2010-06",[666,1862],"Headache",[1845,1864],"Low dose dexamethasone",{"trials":1866,"activeCount":101},[],{"trials":1868,"activeCount":101},[],{"intervention":1864,"totalTrials":97,"cells":1870},{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1877,"PHASE4":1883,"NA":1885},{"trials":1872,"activeCount":101},[],{"trials":1874,"activeCount":101},[],{"trials":1876,"activeCount":101},[],{"trials":1878,"activeCount":101},[1879],{"nctId":1856,"briefTitle":1857,"status":592,"phases":1880,"primaryCompletion":1859,"completion":1859,"start":1860,"enrollment":16,"conditions":1881,"interventions":1882},[91],[666,1862],[1845,1864],{"trials":1884,"activeCount":101},[],{"trials":1886,"activeCount":101},[],{"intervention":1129,"totalTrials":97,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":101},[],{"trials":1892,"activeCount":101},[],{"trials":1894,"activeCount":101},[],{"trials":1896,"activeCount":101},[1897],{"nctId":1120,"briefTitle":1121,"status":170,"phases":1898,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":218,"conditions":1899,"interventions":1900},[91],[1126],[1128,1129],{"trials":1902,"activeCount":101},[],{"trials":1904,"activeCount":101},[],{"intervention":1906,"totalTrials":97,"cells":1907},"fluvoxamine",{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1925,"NA":1927},{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[],{"trials":1915,"activeCount":101},[1916],{"nctId":1917,"briefTitle":1918,"status":170,"phases":1919,"primaryCompletion":978,"completion":1253,"start":1920,"enrollment":1435,"conditions":1921,"interventions":1923},"NCT00655174","Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and\u002For Mood?",[91],"1999-06",[1922],"Autism",[1906,1924],"sertraline",{"trials":1926,"activeCount":101},[],{"trials":1928,"activeCount":101},[],{"intervention":1924,"totalTrials":97,"cells":1930},{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1943,"NA":1945},{"trials":1932,"activeCount":101},[],{"trials":1934,"activeCount":101},[],{"trials":1936,"activeCount":101},[],{"trials":1938,"activeCount":101},[1939],{"nctId":1917,"briefTitle":1918,"status":170,"phases":1940,"primaryCompletion":978,"completion":1253,"start":1920,"enrollment":1435,"conditions":1941,"interventions":1942},[91],[1922],[1906,1924],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[],{"intervention":1948,"totalTrials":97,"cells":1949},"MAS825",{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1967,"NA":1969},{"trials":1951,"activeCount":101},[],{"trials":1953,"activeCount":101},[],{"trials":1955,"activeCount":101},[],{"trials":1957,"activeCount":101},[1958],{"nctId":1959,"briefTitle":1960,"status":170,"phases":1961,"primaryCompletion":1962,"completion":1962,"start":1963,"enrollment":97,"conditions":1964,"interventions":1966},"NCT06309823","A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency",[91],"2024-01-17","2023-02-08",[1965],"X-linked Lymphoproliferative Syndrome Type 2 (XLP-2)",[1948],{"trials":1968,"activeCount":101},[],{"trials":1970,"activeCount":101},[],{"intervention":1972,"totalTrials":97,"cells":1973},"varicella vaccine",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1990,"NA":1992},{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[1982],{"nctId":1983,"briefTitle":1984,"status":170,"phases":1985,"primaryCompletion":909,"completion":909,"start":1920,"enrollment":1986,"conditions":1987,"interventions":1989},"NCT00213304","The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation",[91],21,[1988,1394],"Organ Transplantation",[1972],{"trials":1991,"activeCount":101},[],{"trials":1993,"activeCount":101},[],{"intervention":1995,"totalTrials":97,"cells":1996},"Enalaprilat",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2014,"NA":2016},{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[],{"trials":2004,"activeCount":101},[2005],{"nctId":2006,"briefTitle":2007,"status":170,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":867,"enrollment":954,"conditions":2010,"interventions":2013},"NCT00741156","The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution",[91],"2010-01",[2011,2012],"Hypertension","Congestive Cardiomyopathy",[1995],{"trials":2015,"activeCount":101},[],{"trials":2017,"activeCount":101},[],{"intervention":2019,"totalTrials":97,"cells":2020},"darbepoetin alfa",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2039,"NA":2041},{"trials":2022,"activeCount":101},[],{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":101},[2029],{"nctId":2030,"briefTitle":2031,"status":170,"phases":2032,"primaryCompletion":1111,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT00213291","Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure",[91],"2005-10","2005-04",40,[2037],"Kidney Failure, Chronic",[2019],{"trials":2040,"activeCount":101},[],{"trials":2042,"activeCount":101},[],{"intervention":2044,"totalTrials":97,"cells":2045},"Liposomal lidocaine",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2063,"NA":2065},{"trials":2047,"activeCount":101},[],{"trials":2049,"activeCount":101},[],{"trials":2051,"activeCount":101},[],{"trials":2053,"activeCount":101},[2054],{"nctId":2055,"briefTitle":2056,"status":170,"phases":2057,"primaryCompletion":1204,"completion":1204,"start":2058,"enrollment":1087,"conditions":2059,"interventions":2061},"NCT01006187","Comparison of Different Methods for Reducing Pain From Influenza Vaccine Injections",[91],"2009-10",[18,2060],"Anxiety",[2044,2062],"Vapocoolant spray",{"trials":2064,"activeCount":101},[],{"trials":2066,"activeCount":101},[],{"intervention":2062,"totalTrials":97,"cells":2068},{"EARLY_PHASE1":2069,"PHASE1":2071,"PHASE2":2073,"PHASE3":2075,"PHASE4":2081,"NA":2083},{"trials":2070,"activeCount":101},[],{"trials":2072,"activeCount":101},[],{"trials":2074,"activeCount":101},[],{"trials":2076,"activeCount":101},[2077],{"nctId":2055,"briefTitle":2056,"status":170,"phases":2078,"primaryCompletion":1204,"completion":1204,"start":2058,"enrollment":1087,"conditions":2079,"interventions":2080},[91],[18,2060],[2044,2062],{"trials":2082,"activeCount":101},[],{"trials":2084,"activeCount":101},[],{"intervention":2086,"totalTrials":97,"cells":2087},"High Dose Methotrexate",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2105,"NA":2107},{"trials":2089,"activeCount":101},[],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":101},[],{"trials":2095,"activeCount":101},[2096],{"nctId":2097,"briefTitle":2098,"status":170,"phases":2099,"primaryCompletion":2100,"completion":2100,"start":2101,"enrollment":1345,"conditions":2102,"interventions":2104},"NCT01176981","Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma",[91],"2012-10","2010-10",[2103],"Osteosarcoma",[2086],{"trials":2106,"activeCount":101},[],{"trials":2108,"activeCount":101},[],{"intervention":2110,"totalTrials":97,"cells":2111},"Enfalyte",{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2116,"PHASE3":2118,"PHASE4":2129,"NA":2131},{"trials":2113,"activeCount":101},[],{"trials":2115,"activeCount":101},[],{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":101},[2120],{"nctId":2121,"briefTitle":2122,"status":170,"phases":2123,"primaryCompletion":1522,"completion":1522,"start":1180,"enrollment":2124,"conditions":2125,"interventions":2126},"NCT00689312","Palatability of Oral Rehydration Solutions",[91],66,[711],[2110,2127,2128],"Pediatric Electrolyte","Pedialyte",{"trials":2130,"activeCount":101},[],{"trials":2132,"activeCount":101},[],{"intervention":2127,"totalTrials":97,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2147,"NA":2149},{"trials":2136,"activeCount":101},[],{"trials":2138,"activeCount":101},[],{"trials":2140,"activeCount":101},[],{"trials":2142,"activeCount":101},[2143],{"nctId":2121,"briefTitle":2122,"status":170,"phases":2144,"primaryCompletion":1522,"completion":1522,"start":1180,"enrollment":2124,"conditions":2145,"interventions":2146},[91],[711],[2110,2127,2128],{"trials":2148,"activeCount":101},[],{"trials":2150,"activeCount":101},[],{"intervention":2128,"totalTrials":97,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2165,"NA":2167},{"trials":2154,"activeCount":101},[],{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":101},[],{"trials":2160,"activeCount":101},[2161],{"nctId":2121,"briefTitle":2122,"status":170,"phases":2162,"primaryCompletion":1522,"completion":1522,"start":1180,"enrollment":2124,"conditions":2163,"interventions":2164},[91],[711],[2110,2127,2128],{"trials":2166,"activeCount":101},[],{"trials":2168,"activeCount":101},[],{"intervention":177,"totalTrials":97,"cells":2170},{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2177,"PHASE4":2183,"NA":2185},{"trials":2172,"activeCount":101},[],{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":101},[],{"trials":2178,"activeCount":101},[2179],{"nctId":168,"briefTitle":169,"status":170,"phases":2180,"primaryCompletion":172,"completion":172,"start":173,"enrollment":9,"conditions":2181,"interventions":2182},[91],[175],[56,177],{"trials":2184,"activeCount":101},[],{"trials":2186,"activeCount":101},[],{"intervention":2188,"totalTrials":97,"cells":2189},"Imiquimod 5% cream",{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2206,"NA":2208},{"trials":2191,"activeCount":101},[],{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[],{"trials":2197,"activeCount":101},[2198],{"nctId":2199,"briefTitle":2200,"status":170,"phases":2201,"primaryCompletion":2202,"completion":2202,"start":1111,"enrollment":464,"conditions":2203,"interventions":2205},"NCT00147771","Imiquimod in Children With Plaque Morphea",[91],"2009-09",[2204],"Scleroderma, Localized",[2188],{"trials":2207,"activeCount":101},[],{"trials":2209,"activeCount":101},[],{"intervention":2211,"totalTrials":97,"cells":2212},"Tranexamic Acid",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2232,"NA":2234},{"trials":2214,"activeCount":101},[],{"trials":2216,"activeCount":101},[],{"trials":2218,"activeCount":101},[],{"trials":2220,"activeCount":101},[2221],{"nctId":2222,"briefTitle":2223,"status":2224,"phases":2225,"primaryCompletion":2226,"completion":2226,"start":2009,"enrollment":2227,"conditions":2228,"interventions":2230},"NCT01094977","Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid","SUSPENDED",[91],"2020-01",90,[2229],"Craniosynostoses",[2211,2211,2231],"Saline Placebo",{"trials":2233,"activeCount":101},[],{"trials":2235,"activeCount":101},[],{"intervention":2231,"totalTrials":97,"cells":2237},{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2242,"PHASE3":2244,"PHASE4":2250,"NA":2252},{"trials":2239,"activeCount":101},[],{"trials":2241,"activeCount":101},[],{"trials":2243,"activeCount":101},[],{"trials":2245,"activeCount":101},[2246],{"nctId":2222,"briefTitle":2223,"status":2224,"phases":2247,"primaryCompletion":2226,"completion":2226,"start":2009,"enrollment":2227,"conditions":2248,"interventions":2249},[91],[2229],[2211,2211,2231],{"trials":2251,"activeCount":101},[],{"trials":2253,"activeCount":101},[],{"intervention":2255,"totalTrials":97,"cells":2256},"Hypotonic (0.45% NaCl\u002F5% dextrose) IV maintenance fluids",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2276,"NA":2278},{"trials":2258,"activeCount":101},[],{"trials":2260,"activeCount":101},[],{"trials":2262,"activeCount":101},[],{"trials":2264,"activeCount":101},[2265],{"nctId":2266,"briefTitle":2267,"status":170,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2274},"NCT00632775","0.9% NaCl\u002FDextrose 5% vs 0.45% NaCl\u002FDextrose 5% as Maintenance Intravenous Fluids in Hospitalized Children",[91],"2012-09","2007-12",110,[2273],"Hyponatremia",[2255,2275],"Isotonic (0.9% NaCl\u002F5% dextrose) IV maintenance fluids",{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":101},[],{"intervention":2275,"totalTrials":97,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2294,"NA":2296},{"trials":2283,"activeCount":101},[],{"trials":2285,"activeCount":101},[],{"trials":2287,"activeCount":101},[],{"trials":2289,"activeCount":101},[2290],{"nctId":2266,"briefTitle":2267,"status":170,"phases":2291,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":2271,"conditions":2292,"interventions":2293},[91],[2273],[2255,2275],{"trials":2295,"activeCount":101},[],{"trials":2297,"activeCount":101},[],{"intervention":2299,"totalTrials":97,"cells":2300},"Vitamin D + Calcium + Exercise program + Humatrope",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2307,"PHASE4":2316,"NA":2318},{"trials":2302,"activeCount":101},[],{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":101},[],{"trials":2308,"activeCount":101},[2309],{"nctId":2310,"briefTitle":2311,"status":170,"phases":2312,"primaryCompletion":1216,"completion":1216,"start":1302,"enrollment":1986,"conditions":2313,"interventions":2315},"NCT00757393","Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis",[91],[2314],"Osteoporosis",[2299],{"trials":2317,"activeCount":101},[],{"trials":2319,"activeCount":101},[],{"intervention":1220,"totalTrials":97,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2334,"NA":2336},{"trials":2323,"activeCount":101},[],{"trials":2325,"activeCount":101},[],{"trials":2327,"activeCount":101},[],{"trials":2329,"activeCount":101},[2330],{"nctId":1211,"briefTitle":1212,"status":170,"phases":2331,"primaryCompletion":1214,"completion":1215,"start":1216,"enrollment":1217,"conditions":2332,"interventions":2333},[91],[1206],[1190,1220],{"trials":2335,"activeCount":101},[],{"trials":2337,"activeCount":101},[],{"intervention":2339,"totalTrials":97,"cells":2340},"Diclectin®",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2357,"NA":2359},{"trials":2342,"activeCount":101},[],{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[2349],{"nctId":2350,"briefTitle":2351,"status":170,"phases":2352,"primaryCompletion":1775,"completion":2353,"start":2354,"enrollment":9,"conditions":2355,"interventions":2356},"NCT00293644","Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy",[91],"2015-06","2006-02",[667,28],[2339],{"trials":2358,"activeCount":101},[],{"trials":2360,"activeCount":101},[],{"intervention":2362,"totalTrials":97,"cells":2363},"Pregabalin",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2370,"PHASE4":2384,"NA":2386},{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":101},[],{"trials":2369,"activeCount":101},[],{"trials":2371,"activeCount":101},[2372],{"nctId":2373,"briefTitle":2374,"status":170,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":97,"conditions":2379,"interventions":2383},"NCT03928093","Pregabalin Treatment for RDEB Pain and Itch",[91],"2023-03-01","2024-02-01","2019-08-07",[2380,2381,2382],"Pain, Neuropathic","Itch","Epidermolysis Bullosa",[2362],{"trials":2385,"activeCount":101},[],{"trials":2387,"activeCount":101},[],{"intervention":2389,"totalTrials":97,"cells":2390},"Bovine Lipid Extract Surfactant",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2406,"NA":2408},{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[],{"trials":2396,"activeCount":101},[],{"trials":2398,"activeCount":101},[2399],{"nctId":2400,"briefTitle":2401,"status":607,"phases":2402,"start":450,"enrollment":218,"conditions":2403,"interventions":2405},"NCT00312507","Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration",[91],[2404],"Meconium Aspiration Syndrome",[2389,2389],{"trials":2407,"activeCount":101},[],{"trials":2409,"activeCount":101},[],{"intervention":1090,"totalTrials":97,"cells":2411},{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2418,"PHASE4":2424,"NA":2426},{"trials":2413,"activeCount":101},[],{"trials":2415,"activeCount":101},[],{"trials":2417,"activeCount":101},[],{"trials":2419,"activeCount":101},[2420],{"nctId":1082,"briefTitle":1083,"status":607,"phases":2421,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2422,"interventions":2423},[91],[18],[1090,1091,1092,1051],{"trials":2425,"activeCount":101},[],{"trials":2427,"activeCount":101},[],{"intervention":1092,"totalTrials":97,"cells":2429},{"EARLY_PHASE1":2430,"PHASE1":2432,"PHASE2":2434,"PHASE3":2436,"PHASE4":2442,"NA":2444},{"trials":2431,"activeCount":101},[],{"trials":2433,"activeCount":101},[],{"trials":2435,"activeCount":101},[],{"trials":2437,"activeCount":101},[2438],{"nctId":1082,"briefTitle":1083,"status":607,"phases":2439,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":2440,"interventions":2441},[91],[18],[1090,1091,1092,1051],{"trials":2443,"activeCount":101},[],{"trials":2445,"activeCount":101},[],{"intervention":2447,"totalTrials":97,"cells":2448},"Methylprednisolone and IVIG",{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2467,"NA":2469},{"trials":2450,"activeCount":101},[],{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[2457],{"nctId":2458,"briefTitle":2459,"status":170,"phases":2460,"primaryCompletion":2461,"completion":1085,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2466},"NCT00376077","A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.",[91],"2016-03","2005-08",32,[2465],"Immune Thrombocytopenic Purpura",[2447],{"trials":2468,"activeCount":101},[],{"trials":2470,"activeCount":101},[],{"intervention":2472,"totalTrials":97,"cells":2473},"Sildenafil",{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2478,"PHASE3":2480,"PHASE4":2488,"NA":2490},{"trials":2475,"activeCount":101},[],{"trials":2477,"activeCount":101},[],{"trials":2479,"activeCount":101},[],{"trials":2481,"activeCount":101},[2482],{"nctId":2483,"briefTitle":2484,"status":592,"phases":2485,"primaryCompletion":1458,"completion":1458,"start":1522,"enrollment":464,"conditions":2486,"interventions":2487},"NCT00742014","The Assessment of Right Ventricular Contractility in Response to Sildenafil",[91],[2011],[2472],{"trials":2489,"activeCount":101},[],{"trials":2491,"activeCount":101},[],{"intervention":2493,"totalTrials":97,"cells":2494},"Nicoderm patches",{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2501,"PHASE4":2510,"NA":2512},{"trials":2496,"activeCount":101},[],{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[],{"trials":2502,"activeCount":101},[2503],{"nctId":2504,"briefTitle":2505,"status":1133,"phases":2506,"primaryCompletion":1179,"completion":953,"start":1522,"enrollment":101,"conditions":2507,"interventions":2509},"NCT00744913","Study of Nicotine Replacement Therapy in Pregnancy",[91],[2508],"Smoking Cessation",[2493],{"trials":2511,"activeCount":101},[],{"trials":2513,"activeCount":101},[],{"intervention":2515,"totalTrials":97,"cells":2516},"Propofol 2.0 mg\u002Fkg + Remifentanil 1.5 ug\u002Fkg",{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2523,"PHASE4":2533,"NA":2535},{"trials":2518,"activeCount":101},[],{"trials":2520,"activeCount":101},[],{"trials":2522,"activeCount":101},[],{"trials":2524,"activeCount":101},[2525],{"nctId":2526,"briefTitle":2527,"status":170,"phases":2528,"primaryCompletion":866,"completion":866,"start":708,"enrollment":1170,"conditions":2529,"interventions":2531},"NCT00405522","Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children",[91],[2530],"Spinal Puncture",[2515,2532],"Propofol 4.0 mg\u002Fkg + Remifentanil 0.5 ug\u002Fkg",{"trials":2534,"activeCount":101},[],{"trials":2536,"activeCount":101},[],{"intervention":2532,"totalTrials":97,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2551,"NA":2553},{"trials":2540,"activeCount":101},[],{"trials":2542,"activeCount":101},[],{"trials":2544,"activeCount":101},[],{"trials":2546,"activeCount":101},[2547],{"nctId":2526,"briefTitle":2527,"status":170,"phases":2548,"primaryCompletion":866,"completion":866,"start":708,"enrollment":1170,"conditions":2549,"interventions":2550},[91],[2530],[2515,2532],{"trials":2552,"activeCount":101},[],{"trials":2554,"activeCount":101},[],{"intervention":1140,"totalTrials":97,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":101},[],{"trials":2560,"activeCount":101},[],{"trials":2562,"activeCount":101},[],{"trials":2564,"activeCount":101},[2565],{"nctId":1131,"briefTitle":1132,"status":1133,"phases":2566,"primaryCompletion":1135,"completion":1135,"start":1136,"enrollment":101,"conditions":2567,"interventions":2568},[91],[1138],[1098,1140],{"trials":2570,"activeCount":101},[],{"trials":2572,"activeCount":101},[],{"intervention":1247,"totalTrials":97,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2581,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":101},[],{"trials":2578,"activeCount":101},[],{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[2583],{"nctId":1237,"briefTitle":1238,"status":592,"phases":2584,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":2585,"interventions":2586},[91],[1245],[1247,1226],{"trials":2588,"activeCount":101},[],{"trials":2590,"activeCount":101},[],{"intervention":2592,"totalTrials":97,"cells":2593},"Hydrocortisone 1%",{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2613,"NA":2615},{"trials":2595,"activeCount":101},[],{"trials":2597,"activeCount":101},[],{"trials":2599,"activeCount":101},[],{"trials":2601,"activeCount":101},[2602],{"nctId":2603,"briefTitle":2604,"status":170,"phases":2605,"primaryCompletion":2606,"completion":2606,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2611},"NCT01453686","A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata",[91],"2003-08","2002-08",41,[2610],"Alopecia Areata",[2592,2612],"Clobetasol Propionate 0.05%",{"trials":2614,"activeCount":101},[],{"trials":2616,"activeCount":101},[],{"intervention":2612,"totalTrials":97,"cells":2618},{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2623,"PHASE3":2625,"PHASE4":2631,"NA":2633},{"trials":2620,"activeCount":101},[],{"trials":2622,"activeCount":101},[],{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[2627],{"nctId":2603,"briefTitle":2604,"status":170,"phases":2628,"primaryCompletion":2606,"completion":2606,"start":2607,"enrollment":2608,"conditions":2629,"interventions":2630},[91],[2610],[2592,2612],{"trials":2632,"activeCount":101},[],{"trials":2634,"activeCount":101},[],{"intervention":2636,"totalTrials":97,"cells":2637},"2-octyl cyanoacrylate",{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2642,"PHASE3":2644,"PHASE4":2657,"NA":2659},{"trials":2639,"activeCount":101},[],{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":101},[2646],{"nctId":2647,"briefTitle":2648,"status":607,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":2654,"interventions":2656},"NCT04908137","Use of 2-Octyl Cyanoacrylate (Dermabond) in Neonatal Circumcision: A Randomized Controlled Trial",[91],"2024-03-01","2024-12-31","2021-04-01",280,[2655],"Redundant Prepuce",[2636],{"trials":2658,"activeCount":101},[],{"trials":2660,"activeCount":101},[],{"intervention":1258,"totalTrials":97,"cells":2662},{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2675,"NA":2677},{"trials":2664,"activeCount":101},[],{"trials":2666,"activeCount":101},[],{"trials":2668,"activeCount":101},[],{"trials":2670,"activeCount":101},[2671],{"nctId":1249,"briefTitle":1250,"status":607,"phases":2672,"primaryCompletion":1252,"completion":1020,"start":1253,"enrollment":1254,"conditions":2673,"interventions":2674},[91],[1256],[1258,1226],{"trials":2676,"activeCount":101},[],{"trials":2678,"activeCount":101},[],{"intervention":2680,"totalTrials":145,"cells":2681},"vinblastine sulphate",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2683,"activeCount":101},[],{"trials":2685,"activeCount":101},[],{"trials":2687,"activeCount":101},[2688,2696],{"nctId":2689,"briefTitle":2690,"status":170,"phases":2691,"primaryCompletion":1584,"completion":2269,"start":2692,"enrollment":160,"conditions":2693,"interventions":2695},"NCT00213278","Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma",[90],"2002-01",[2694],"Glioma",[2680],{"nctId":2697,"briefTitle":2698,"status":607,"phases":2699,"primaryCompletion":1343,"completion":2700,"start":2701,"enrollment":160,"conditions":2702,"interventions":2703},"NCT00575796","Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)",[90],"2019-10","2007-10",[2694],[2704],"Vinblastine Sulphate",{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"trials":2710,"activeCount":101},[],{"intervention":2712,"totalTrials":145,"cells":2713},"L-arginine",{"EARLY_PHASE1":2714,"PHASE1":2716,"PHASE2":2718,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[],{"trials":2719,"activeCount":101},[2720,2726],{"nctId":2721,"briefTitle":2722,"status":170,"phases":2723,"primaryCompletion":1020,"completion":1020,"start":708,"enrollment":218,"conditions":2724,"interventions":2725},"NCT00405665","The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis",[90],[20],[2712,2712],{"nctId":2727,"briefTitle":2728,"status":170,"phases":2729,"primaryCompletion":2730,"completion":1859,"start":1774,"enrollment":35,"conditions":2731,"interventions":2733},"NCT01603446","L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome",[90],"2013-05",[2732],"MELAS Syndrome",[2734],"L-Arginine",{"trials":2736,"activeCount":101},[],{"trials":2738,"activeCount":101},[],{"trials":2740,"activeCount":101},[],{"intervention":2742,"totalTrials":97,"cells":2743},"Lacidophil",{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2748,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2745,"activeCount":101},[],{"trials":2747,"activeCount":101},[],{"trials":2749,"activeCount":101},[2750],{"nctId":2751,"briefTitle":2752,"status":592,"phases":2753,"primaryCompletion":2754,"completion":261,"start":2755,"enrollment":2756,"conditions":2757,"interventions":2758},"NCT00760773","Impact of Emergency Department Probiotic Treatment of Diarrheal Illness on Daycare Attendance",[90],"2013-09","2009-04",132,[711],[2742,2742],{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"intervention":2766,"totalTrials":97,"cells":2767},"No supplementation",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2781,"PHASE4":2783,"NA":2785},{"trials":2769,"activeCount":101},[],{"trials":2771,"activeCount":101},[],{"trials":2773,"activeCount":101},[2774],{"nctId":2775,"briefTitle":2776,"status":170,"phases":2777,"primaryCompletion":2058,"completion":1776,"start":1065,"enrollment":1629,"conditions":2778,"interventions":2780},"NCT00911664","Vitamin D Supplementation and CD4 Count in HIV-Infected Children",[90],[2779],"HIV",[2766],{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[],{"trials":2786,"activeCount":101},[],{"intervention":2788,"totalTrials":97,"cells":2789},"miglustat",{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2791,"activeCount":101},[],{"trials":2793,"activeCount":101},[],{"trials":2795,"activeCount":101},[2796],{"nctId":2797,"briefTitle":2798,"status":170,"phases":2799,"primaryCompletion":2755,"completion":2755,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2804},"NCT00418847","Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis",[90],"2004-07",5,[2803],"Gangliosidoses GM2",[2788],{"trials":2806,"activeCount":101},[],{"trials":2808,"activeCount":101},[],{"trials":2810,"activeCount":101},[],{"intervention":2812,"totalTrials":97,"cells":2813},"Nivolumab",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2815,"activeCount":101},[],{"trials":2817,"activeCount":101},[],{"trials":2819,"activeCount":101},[2820],{"nctId":2821,"briefTitle":2822,"status":592,"phases":2823,"primaryCompletion":2824,"completion":2824,"start":2825,"enrollment":24,"conditions":2826,"interventions":2829},"NCT02992964","Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers",[89,90],"2023-11-20","2017-05-15",[2827,2828],"Refractory or Recurrent Hypermutated Malignancies","Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients",[2812],{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"trials":2835,"activeCount":101},[],{"intervention":2837,"totalTrials":97,"cells":2838},"Tacrolimus",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2856,"PHASE4":2858,"NA":2860},{"trials":2840,"activeCount":101},[],{"trials":2842,"activeCount":101},[],{"trials":2844,"activeCount":101},[2845],{"nctId":2846,"briefTitle":2847,"status":170,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":1584,"enrollment":2850,"conditions":2851,"interventions":2855},"NCT01655563","Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation",[90],"2016-02",75,[2852,2853,2854],"Heart Transplantation","Liver Transplantation","Kidney Transplantation",[2837],{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":101},[],{"trials":2861,"activeCount":101},[],{"intervention":2863,"totalTrials":97,"cells":2864},"inhaled nitric oxide",{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2881,"PHASE4":2883,"NA":2885},{"trials":2866,"activeCount":101},[],{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[2871],{"nctId":2872,"briefTitle":2873,"status":607,"phases":2874,"primaryCompletion":2875,"completion":2876,"start":2877,"enrollment":2035,"conditions":2878,"interventions":2880},"NCT05868109","Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA)",[90],"2025-01-31","2026-01-31","2022-08-31",[2879],"Cardiac Arrest",[2863],{"trials":2882,"activeCount":101},[],{"trials":2884,"activeCount":101},[],{"trials":2886,"activeCount":101},[],{"intervention":2888,"totalTrials":97,"cells":2889},"Topotecan and Pazopanib",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2905,"PHASE4":2907,"NA":2909},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":101},[2896],{"nctId":2897,"briefTitle":2898,"status":170,"phases":2899,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":294,"conditions":2902,"interventions":2904},"NCT02303028","Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent\u002FRefractory Solid Tumours",[89,90],"2022-06-17","2015-03",[2903],"Solid Tumors",[2888],{"trials":2906,"activeCount":101},[],{"trials":2908,"activeCount":101},[],{"trials":2910,"activeCount":101},[],{"intervention":2912,"totalTrials":97,"cells":2913},"Thymoglobulin",{"EARLY_PHASE1":2914,"PHASE1":2916,"PHASE2":2918,"PHASE3":2930,"PHASE4":2932,"NA":2934},{"trials":2915,"activeCount":101},[],{"trials":2917,"activeCount":101},[],{"trials":2919,"activeCount":101},[2920],{"nctId":2921,"briefTitle":2922,"status":592,"phases":2923,"primaryCompletion":2924,"completion":2924,"start":1204,"enrollment":294,"conditions":2925,"interventions":2929},"NCT01135537","Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants",[90],"2014-01",[2926,2927,2928],"Malignancy","Metabolic Disease","Genetic Disorder",[2912],{"trials":2931,"activeCount":101},[],{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"intervention":2937,"totalTrials":97,"cells":2938},"Maternal Hyperoxygenation",{"EARLY_PHASE1":2939,"PHASE1":2941,"PHASE2":2943,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2940,"activeCount":101},[],{"trials":2942,"activeCount":101},[],{"trials":2944,"activeCount":101},[2945],{"nctId":2946,"briefTitle":2947,"status":170,"phases":2948,"primaryCompletion":388,"completion":388,"start":2949,"enrollment":16,"conditions":2950,"interventions":2952},"NCT03136835","Maternal Hyperoxygenation in Congenital Heart Disease",[89,90],"2018-02-02",[2951],"Hypoplastic Left Heart Syndrome",[2937],{"trials":2954,"activeCount":101},[],{"trials":2956,"activeCount":101},[],{"trials":2958,"activeCount":101},[],{"intervention":2960,"totalTrials":97,"cells":2961},"filgrastim",{"EARLY_PHASE1":2962,"PHASE1":2964,"PHASE2":2966,"PHASE3":2982,"PHASE4":2984,"NA":2986},{"trials":2963,"activeCount":101},[],{"trials":2965,"activeCount":101},[],{"trials":2967,"activeCount":101},[2968],{"nctId":2969,"briefTitle":2970,"status":607,"phases":2971,"primaryCompletion":2972,"completion":2651,"start":2973,"enrollment":2974,"conditions":2975,"interventions":2977},"NCT00110110","Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma",[90],"2016-04-20","2004-06",71,[2976],"Retinoblastoma",[2960,2978,2979,2980,2981],"Carboplatin","Cyclosporine","Etoposide","vincristine sulfate",{"trials":2983,"activeCount":101},[],{"trials":2985,"activeCount":101},[],{"trials":2987,"activeCount":101},[],{"intervention":2978,"totalTrials":97,"cells":2989},{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":3000,"PHASE4":3002,"NA":3004},{"trials":2991,"activeCount":101},[],{"trials":2993,"activeCount":101},[],{"trials":2995,"activeCount":101},[2996],{"nctId":2969,"briefTitle":2970,"status":607,"phases":2997,"primaryCompletion":2972,"completion":2651,"start":2973,"enrollment":2974,"conditions":2998,"interventions":2999},[90],[2976],[2960,2978,2979,2980,2981],{"trials":3001,"activeCount":101},[],{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[],{"intervention":2979,"totalTrials":97,"cells":3007},{"EARLY_PHASE1":3008,"PHASE1":3010,"PHASE2":3012,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[3014],{"nctId":2969,"briefTitle":2970,"status":607,"phases":3015,"primaryCompletion":2972,"completion":2651,"start":2973,"enrollment":2974,"conditions":3016,"interventions":3017},[90],[2976],[2960,2978,2979,2980,2981],{"trials":3019,"activeCount":101},[],{"trials":3021,"activeCount":101},[],{"trials":3023,"activeCount":101},[],{"intervention":2980,"totalTrials":97,"cells":3025},{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3030,"PHASE3":3036,"PHASE4":3038,"NA":3040},{"trials":3027,"activeCount":101},[],{"trials":3029,"activeCount":101},[],{"trials":3031,"activeCount":101},[3032],{"nctId":2969,"briefTitle":2970,"status":607,"phases":3033,"primaryCompletion":2972,"completion":2651,"start":2973,"enrollment":2974,"conditions":3034,"interventions":3035},[90],[2976],[2960,2978,2979,2980,2981],{"trials":3037,"activeCount":101},[],{"trials":3039,"activeCount":101},[],{"trials":3041,"activeCount":101},[],{"intervention":2981,"totalTrials":97,"cells":3043},{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3054,"PHASE4":3056,"NA":3058},{"trials":3045,"activeCount":101},[],{"trials":3047,"activeCount":101},[],{"trials":3049,"activeCount":101},[3050],{"nctId":2969,"briefTitle":2970,"status":607,"phases":3051,"primaryCompletion":2972,"completion":2651,"start":2973,"enrollment":2974,"conditions":3052,"interventions":3053},[90],[2976],[2960,2978,2979,2980,2981],{"trials":3055,"activeCount":101},[],{"trials":3057,"activeCount":101},[],{"trials":3059,"activeCount":101},[],{"intervention":1116,"totalTrials":97,"cells":3061},{"EARLY_PHASE1":3062,"PHASE1":3064,"PHASE2":3066,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3063,"activeCount":101},[],{"trials":3065,"activeCount":101},[],{"trials":3067,"activeCount":101},[3068],{"nctId":1107,"briefTitle":1108,"status":170,"phases":3069,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":1112,"conditions":3070,"interventions":3071},[90],[1114],[1116,1098],{"trials":3073,"activeCount":101},[],{"trials":3075,"activeCount":101},[],{"trials":3077,"activeCount":101},[],{"intervention":3079,"totalTrials":97,"cells":3080},"Carvedilol",{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3082,"activeCount":101},[],{"trials":3084,"activeCount":101},[],{"trials":3086,"activeCount":101},[3087],{"nctId":3088,"briefTitle":3089,"status":1133,"phases":3090,"primaryCompletion":1216,"start":2269,"enrollment":101,"conditions":3091,"interventions":3093},"NCT01723371","Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children",[89,90],[3092],"Pulmonary Arterial Hypertension",[3079],{"trials":3095,"activeCount":101},[],{"trials":3097,"activeCount":101},[],{"trials":3099,"activeCount":101},[],{"intervention":3101,"totalTrials":97,"cells":3102},"Intralipid 20%",{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3107,"PHASE3":3122,"PHASE4":3124,"NA":3126},{"trials":3104,"activeCount":101},[],{"trials":3106,"activeCount":101},[],{"trials":3108,"activeCount":101},[3109],{"nctId":3110,"briefTitle":3111,"status":607,"phases":3112,"primaryCompletion":1584,"completion":3113,"start":3114,"enrollment":240,"conditions":3115,"interventions":3120},"NCT00793195","Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?",[90],"2012-01","2009-01",[3116,3117,3118,3119],"Short Bowel Syndrome","Intestinal Failure","Gastrointestinal Motility Disorder","Mucosal Enteropathy",[3101,3121],"SMOFlipid 20%",{"trials":3123,"activeCount":101},[],{"trials":3125,"activeCount":101},[],{"trials":3127,"activeCount":101},[],{"intervention":3121,"totalTrials":97,"cells":3129},{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3131,"activeCount":101},[],{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[3136],{"nctId":3110,"briefTitle":3111,"status":607,"phases":3137,"primaryCompletion":1584,"completion":3113,"start":3114,"enrollment":240,"conditions":3138,"interventions":3139},[90],[3116,3117,3118,3119],[3101,3121],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":101},[],{"trials":3145,"activeCount":101},[],{"intervention":3147,"totalTrials":97,"cells":3148},"129Xenon",{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3164,"PHASE4":3166,"NA":3168},{"trials":3150,"activeCount":101},[],{"trials":3152,"activeCount":101},[],{"trials":3154,"activeCount":101},[3155],{"nctId":3156,"briefTitle":3157,"status":592,"phases":3158,"primaryCompletion":3159,"completion":3159,"start":3160,"enrollment":1345,"conditions":3161,"interventions":3163},"NCT05550662","HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients",[90],"2024-08-02","2024-02-07",[3162],"Lung Transplant Rejection",[3147],{"trials":3165,"activeCount":101},[],{"trials":3167,"activeCount":101},[],{"trials":3169,"activeCount":101},[],{"intervention":3171,"totalTrials":97,"cells":3172},"Remifentanil",{"EARLY_PHASE1":3173,"PHASE1":3175,"PHASE2":3177,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3174,"activeCount":101},[],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[3179],{"nctId":3180,"briefTitle":3181,"status":170,"phases":3182,"primaryCompletion":977,"completion":226,"start":1111,"enrollment":1254,"conditions":3183,"interventions":3186},"NCT00213239","A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children",[89,90],[3184,3185],"Hematologic Diseases","Neoplasms",[3171,3171],{"trials":3188,"activeCount":101},[],{"trials":3190,"activeCount":101},[],{"trials":3192,"activeCount":101},[],{"intervention":3194,"totalTrials":97,"cells":3195},"Tranexamic acid 10mg\u002Fkg\u002Fhr",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[3202],{"nctId":3203,"briefTitle":3204,"status":592,"phases":3205,"primaryCompletion":610,"completion":610,"start":610,"enrollment":145,"conditions":3206,"interventions":3208},"NCT01089140","Non-Idiopathic Scoliosis Treated With Tranexamic Acid",[90],[3207],"Non-idiopathic Scoliosis",[3194,3209,3210],"Tranexamic acid 100 mg\u002Fkg\u002Fh","Saline solution",{"trials":3212,"activeCount":101},[],{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":101},[],{"intervention":3209,"totalTrials":97,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":101},[3225],{"nctId":3203,"briefTitle":3204,"status":592,"phases":3226,"primaryCompletion":610,"completion":610,"start":610,"enrollment":145,"conditions":3227,"interventions":3228},[90],[3207],[3194,3209,3210],{"trials":3230,"activeCount":101},[],{"trials":3232,"activeCount":101},[],{"trials":3234,"activeCount":101},[],{"intervention":3210,"totalTrials":97,"cells":3236},{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3247,"PHASE4":3249,"NA":3251},{"trials":3238,"activeCount":101},[],{"trials":3240,"activeCount":101},[],{"trials":3242,"activeCount":101},[3243],{"nctId":3203,"briefTitle":3204,"status":592,"phases":3244,"primaryCompletion":610,"completion":610,"start":610,"enrollment":145,"conditions":3245,"interventions":3246},[90],[3207],[3194,3209,3210],{"trials":3248,"activeCount":101},[],{"trials":3250,"activeCount":101},[],{"trials":3252,"activeCount":101},[],{"intervention":3254,"totalTrials":97,"cells":3255},"Trimethoprim",{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3257,"activeCount":101},[],{"trials":3259,"activeCount":101},[],{"trials":3261,"activeCount":101},[3262],{"nctId":3263,"briefTitle":3264,"status":170,"phases":3265,"primaryCompletion":1066,"completion":977,"start":978,"enrollment":464,"conditions":3266,"interventions":3267},"NCT00380640","The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa",[90],[2382],[3254,3254],{"trials":3269,"activeCount":101},[],{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":101},[],{"intervention":3275,"totalTrials":97,"cells":3276},"Omega Pure followed by placebo",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3292,"PHASE4":3294,"NA":3296},{"trials":3278,"activeCount":101},[],{"trials":3280,"activeCount":101},[],{"trials":3282,"activeCount":101},[3283],{"nctId":3284,"briefTitle":3285,"status":592,"phases":3286,"primaryCompletion":3287,"completion":636,"start":3288,"enrollment":1777,"conditions":3289,"interventions":3291},"NCT00691288","Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children",[90],"2011-10","2008-06",[3290],"Hypertriglyceridemia",[3275],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[],{"trials":3297,"activeCount":101},[],{"intervention":3299,"totalTrials":97,"cells":3300},"Pyrimethamine",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3302,"activeCount":101},[],{"trials":3304,"activeCount":101},[],{"trials":3306,"activeCount":101},[3307],{"nctId":3308,"briefTitle":3309,"status":170,"phases":3310,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":218,"conditions":3313,"interventions":3317},"NCT01102686","Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)",[89,90],"2010-11","2009-08",[3314,3315,3316],"Gangliosidoses, GM2","Sandhoff Disease","Tay-Sachs Disease",[3299,3318],"Leucovorin",{"trials":3320,"activeCount":101},[],{"trials":3322,"activeCount":101},[],{"trials":3324,"activeCount":101},[],{"intervention":3318,"totalTrials":97,"cells":3326},{"EARLY_PHASE1":3327,"PHASE1":3329,"PHASE2":3331,"PHASE3":3337,"PHASE4":3339,"NA":3341},{"trials":3328,"activeCount":101},[],{"trials":3330,"activeCount":101},[],{"trials":3332,"activeCount":101},[3333],{"nctId":3308,"briefTitle":3309,"status":170,"phases":3334,"primaryCompletion":3311,"completion":3311,"start":3312,"enrollment":218,"conditions":3335,"interventions":3336},[89,90],[3314,3315,3316],[3299,3318],{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[],{"intervention":231,"totalTrials":97,"cells":3344},{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3349,"PHASE3":3355,"PHASE4":3357,"NA":3359},{"trials":3346,"activeCount":101},[],{"trials":3348,"activeCount":101},[],{"trials":3350,"activeCount":101},[3351],{"nctId":223,"briefTitle":224,"status":170,"phases":3352,"primaryCompletion":226,"completion":226,"start":227,"enrollment":29,"conditions":3353,"interventions":3354},[90],[229],[231,203],{"trials":3356,"activeCount":101},[],{"trials":3358,"activeCount":101},[],{"trials":3360,"activeCount":101},[],{"intervention":3362,"totalTrials":97,"cells":3363},"Captopril",{"EARLY_PHASE1":3364,"PHASE1":3366,"PHASE2":3368,"PHASE3":3377,"PHASE4":3379,"NA":3381},{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[],{"trials":3369,"activeCount":101},[3370],{"nctId":3371,"briefTitle":3372,"status":607,"phases":3373,"primaryCompletion":3312,"completion":1178,"start":1522,"enrollment":160,"conditions":3374,"interventions":3376},"NCT00742040","Rapid Versus Prolonged Inpatient Up-Titration of Captopril",[90],[3375],"Heart Disease",[3362,3362],{"trials":3378,"activeCount":101},[],{"trials":3380,"activeCount":101},[],{"trials":3382,"activeCount":101},[],{"intervention":3384,"totalTrials":97,"cells":3385},"Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS",{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3401,"PHASE4":3403,"NA":3405},{"trials":3387,"activeCount":101},[],{"trials":3389,"activeCount":101},[],{"trials":3391,"activeCount":101},[3392],{"nctId":3393,"briefTitle":3394,"status":170,"phases":3395,"primaryCompletion":3396,"completion":3396,"start":867,"enrollment":3397,"conditions":3398,"interventions":3400},"NCT00717626","Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A",[90],"2011-04",14,[3399],"Hemophilia A",[3384],{"trials":3402,"activeCount":101},[],{"trials":3404,"activeCount":101},[],{"trials":3406,"activeCount":101},[],{"intervention":3408,"totalTrials":97,"cells":3409},"Hypertonic Saline 7%",{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3424,"PHASE4":3426,"NA":3428},{"trials":3411,"activeCount":101},[],{"trials":3413,"activeCount":101},[],{"trials":3415,"activeCount":101},[3416],{"nctId":3417,"briefTitle":3418,"status":170,"phases":3419,"primaryCompletion":3420,"completion":3420,"start":1279,"enrollment":240,"conditions":3421,"interventions":3422},"NCT02276898","A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index",[90],"2014-09",[20],[3408,3423],"Isotonic Saline 0.9%",{"trials":3425,"activeCount":101},[],{"trials":3427,"activeCount":101},[],{"trials":3429,"activeCount":101},[],{"intervention":3423,"totalTrials":97,"cells":3431},{"EARLY_PHASE1":3432,"PHASE1":3434,"PHASE2":3436,"PHASE3":3442,"PHASE4":3444,"NA":3446},{"trials":3433,"activeCount":101},[],{"trials":3435,"activeCount":101},[],{"trials":3437,"activeCount":101},[3438],{"nctId":3417,"briefTitle":3418,"status":170,"phases":3439,"primaryCompletion":3420,"completion":3420,"start":1279,"enrollment":240,"conditions":3440,"interventions":3441},[90],[20],[3408,3423],{"trials":3443,"activeCount":101},[],{"trials":3445,"activeCount":101},[],{"trials":3447,"activeCount":101},[],{"intervention":3449,"totalTrials":97,"cells":3450},"Magnesium Sulfate Sandoz",{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3455,"PHASE3":3469,"PHASE4":3471,"NA":3473},{"trials":3452,"activeCount":101},[],{"trials":3454,"activeCount":101},[],{"trials":3456,"activeCount":101},[3457],{"nctId":3458,"briefTitle":3459,"status":170,"phases":3460,"primaryCompletion":3461,"completion":3462,"start":3463,"enrollment":3464,"conditions":3465,"interventions":3467},"NCT01429415","Magnesium Nebulization Utilization in Management of Pediatric Asthma",[90],"2019-11-19","2019-11-22","2011-09-26",818,[3466],"Acute Asthma",[3449,3468],"Sodium Chloride , USP PPC",{"trials":3470,"activeCount":101},[],{"trials":3472,"activeCount":101},[],{"trials":3474,"activeCount":101},[],{"intervention":3468,"totalTrials":97,"cells":3476},{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[3483],{"nctId":3458,"briefTitle":3459,"status":170,"phases":3484,"primaryCompletion":3461,"completion":3462,"start":3463,"enrollment":3464,"conditions":3485,"interventions":3486},[90],[3466],[3449,3468],{"trials":3488,"activeCount":101},[],{"trials":3490,"activeCount":101},[],{"trials":3492,"activeCount":101},[],{"intervention":3494,"totalTrials":97,"cells":3495},"Biogaia L. reuteri DSM 17938",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3512,"PHASE4":3514,"NA":3516},{"trials":3497,"activeCount":101},[],{"trials":3499,"activeCount":101},[],{"trials":3501,"activeCount":101},[3502],{"nctId":3503,"briefTitle":3504,"status":170,"phases":3505,"primaryCompletion":3506,"completion":3506,"start":1279,"enrollment":3507,"conditions":3508,"interventions":3510},"NCT01541046","Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic",[90],"2014-06",55,[3509],"Colic",[3494,3511],"Probiotic Placebo",{"trials":3513,"activeCount":101},[],{"trials":3515,"activeCount":101},[],{"trials":3517,"activeCount":101},[],{"intervention":3511,"totalTrials":97,"cells":3519},{"EARLY_PHASE1":3520,"PHASE1":3522,"PHASE2":3524,"PHASE3":3530,"PHASE4":3532,"NA":3534},{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[],{"trials":3525,"activeCount":101},[3526],{"nctId":3503,"briefTitle":3504,"status":170,"phases":3527,"primaryCompletion":3506,"completion":3506,"start":1279,"enrollment":3507,"conditions":3528,"interventions":3529},[90],[3509],[3494,3511],{"trials":3531,"activeCount":101},[],{"trials":3533,"activeCount":101},[],{"trials":3535,"activeCount":101},[],{"intervention":3537,"totalTrials":97,"cells":3538},"Oral Aprepitant",{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3540,"activeCount":101},[],{"trials":3542,"activeCount":101},[],{"trials":3544,"activeCount":101},[3545],{"nctId":3546,"briefTitle":3547,"status":592,"phases":3548,"primaryCompletion":3549,"completion":3549,"start":2101,"enrollment":3550,"conditions":3551,"interventions":3553},"NCT01249001","Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents",[90],"2016-09-28",4,[273,666,3552],"Chemotherapy",[3537,3554],"Aprepitant",{"trials":3556,"activeCount":101},[],{"trials":3558,"activeCount":101},[],{"trials":3560,"activeCount":101},[],{"intervention":3554,"totalTrials":97,"cells":3562},{"EARLY_PHASE1":3563,"PHASE1":3565,"PHASE2":3567,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3564,"activeCount":101},[],{"trials":3566,"activeCount":101},[],{"trials":3568,"activeCount":101},[3569],{"nctId":3546,"briefTitle":3547,"status":592,"phases":3570,"primaryCompletion":3549,"completion":3549,"start":2101,"enrollment":3550,"conditions":3571,"interventions":3572},[90],[273,666,3552],[3537,3554],{"trials":3574,"activeCount":101},[],{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[],{"intervention":3580,"totalTrials":97,"cells":3581},"Convalescent plasma",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3599,"PHASE4":3601,"NA":3603},{"trials":3583,"activeCount":101},[],{"trials":3585,"activeCount":101},[],{"trials":3587,"activeCount":101},[3588],{"nctId":3589,"briefTitle":3590,"status":1133,"phases":3591,"primaryCompletion":3592,"completion":3593,"start":3594,"enrollment":101,"conditions":3595,"interventions":3598},"NCT04377568","Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children",[90],"2021-12-01","2022-05-01","2020-10-07",[3596,3597],"Hospitalized Children","Covid-19 Infection",[3580],{"trials":3600,"activeCount":101},[],{"trials":3602,"activeCount":101},[],{"trials":3604,"activeCount":101},[],{"intervention":3606,"totalTrials":97,"cells":3607},"Perindopril",{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3609,"activeCount":101},[],{"trials":3611,"activeCount":101},[],{"trials":3613,"activeCount":101},[3614],{"nctId":3615,"briefTitle":3616,"status":1133,"phases":3617,"primaryCompletion":3618,"completion":3618,"start":2754,"enrollment":101,"conditions":3619,"interventions":3621},"NCT01948232","Pilot Study of Perindopril in Childhood Cancer Survivors",[90],"2015-07",[3620],"Childhood Cancer Survivors",[3606],{"trials":3623,"activeCount":101},[],{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[],{"intervention":3629,"totalTrials":97,"cells":3630},"Magnesium",{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3635,"PHASE3":3643,"PHASE4":3645,"NA":3647},{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":101},[],{"trials":3636,"activeCount":101},[3637],{"nctId":3638,"briefTitle":3639,"status":170,"phases":3640,"primaryCompletion":1775,"completion":636,"start":1860,"enrollment":2801,"conditions":3641,"interventions":3642},"NCT01148888","The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery",[90],[1183],[3629],{"trials":3644,"activeCount":101},[],{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":101},[],{"intervention":3650,"totalTrials":97,"cells":3651},"Human milk-dissolved amoxicillin",{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3656,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3653,"activeCount":101},[],{"trials":3655,"activeCount":101},[],{"trials":3657,"activeCount":101},[3658],{"nctId":3659,"briefTitle":3660,"status":170,"phases":3661,"primaryCompletion":2754,"completion":796,"start":3662,"enrollment":21,"conditions":3663,"interventions":3664},"NCT01435824","Bioavailability of Amoxicillin Dissolved in Human Milk",[90],"2011-06",[15],[3650,3665],"Water-dissolved amoxicillin",{"trials":3667,"activeCount":101},[],{"trials":3669,"activeCount":101},[],{"trials":3671,"activeCount":101},[],{"intervention":3665,"totalTrials":97,"cells":3673},{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3678,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3675,"activeCount":101},[],{"trials":3677,"activeCount":101},[],{"trials":3679,"activeCount":101},[3680],{"nctId":3659,"briefTitle":3660,"status":170,"phases":3681,"primaryCompletion":2754,"completion":796,"start":3662,"enrollment":21,"conditions":3682,"interventions":3683},[90],[15],[3650,3665],{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[],{"trials":3689,"activeCount":101},[],{"intervention":3691,"totalTrials":97,"cells":3692},"Milrinone",{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[3699],{"nctId":3700,"briefTitle":3701,"status":170,"phases":3702,"primaryCompletion":3703,"completion":3703,"start":823,"enrollment":3704,"conditions":3705,"interventions":3706},"NCT01841177","Evaluating Precision of Therapy - Milrinone",[90],"2020-08",52,[23],[3691],{"trials":3708,"activeCount":101},[],{"trials":3710,"activeCount":101},[],{"trials":3712,"activeCount":101},[],{"intervention":3714,"totalTrials":97,"cells":3715},"Hydroxychloroquine",{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3720,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3717,"activeCount":101},[],{"trials":3719,"activeCount":101},[],{"trials":3721,"activeCount":101},[3722],{"nctId":3723,"briefTitle":3724,"status":170,"phases":3725,"primaryCompletion":3726,"completion":3726,"start":3727,"enrollment":204,"conditions":3728,"interventions":3731},"NCT03856866","Hydroxychloroquine Administration for Reduction of Pexophagy",[90],"2020-05-05","2019-01-11",[3729,3730],"Zellweger Syndrome","Peroxisome Biogenesis Disorders",[3714],{"trials":3733,"activeCount":101},[],{"trials":3735,"activeCount":101},[],{"trials":3737,"activeCount":101},[],{"intervention":3739,"totalTrials":97,"cells":3740},"Nutrient-enriched human milk",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3742,"activeCount":101},[],{"trials":3744,"activeCount":101},[],{"trials":3746,"activeCount":101},[3747],{"nctId":3748,"briefTitle":3749,"status":170,"phases":3750,"primaryCompletion":3751,"start":3752,"enrollment":2035,"conditions":3753,"interventions":3755},"NCT00413985","Post Discharge Human Milk Fortifier in Preterm Infants",[90],"2007-11","2004-01",[3754],"Infant, Low Birth Weight",[3739],{"trials":3757,"activeCount":101},[],{"trials":3759,"activeCount":101},[],{"trials":3761,"activeCount":101},[],{"intervention":3763,"totalTrials":97,"cells":3764},"Acarbose",{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3778,"PHASE4":3780,"NA":3782},{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"trials":3770,"activeCount":101},[3771],{"nctId":3772,"briefTitle":3773,"status":592,"phases":3774,"primaryCompletion":1522,"completion":1522,"start":1253,"enrollment":97,"conditions":3775,"interventions":3777},"NCT00677521","A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)",[90],[3776],"Non-alcoholic Fatty Liver Disease",[3763],{"trials":3779,"activeCount":101},[],{"trials":3781,"activeCount":101},[],{"trials":3783,"activeCount":101},[],{"intervention":3785,"totalTrials":97,"cells":3786},"Losartan",{"EARLY_PHASE1":3787,"PHASE1":3789,"PHASE2":3791,"PHASE3":3802,"PHASE4":3804,"NA":3806},{"trials":3788,"activeCount":101},[],{"trials":3790,"activeCount":101},[],{"trials":3792,"activeCount":101},[3793],{"nctId":3794,"briefTitle":3795,"status":2224,"phases":3796,"primaryCompletion":3797,"completion":3797,"start":1240,"enrollment":2035,"conditions":3798,"interventions":3801},"NCT02769130","Pilot Trial: the Safety and Feasibility of Losartan for Pulmonary Vein Stenosis",[89,90],"2021-05",[3799,3800],"Pulmonary Vein Stenosis","Children",[3785],{"trials":3803,"activeCount":101},[],{"trials":3805,"activeCount":101},[],{"trials":3807,"activeCount":101},[],{"intervention":599,"totalTrials":97,"cells":3809},{"EARLY_PHASE1":3810,"PHASE1":3812,"PHASE2":3814,"PHASE3":3820,"PHASE4":3822,"NA":3824},{"trials":3811,"activeCount":101},[],{"trials":3813,"activeCount":101},[],{"trials":3815,"activeCount":101},[3816],{"nctId":590,"briefTitle":591,"status":592,"phases":3817,"primaryCompletion":594,"completion":594,"start":595,"enrollment":262,"conditions":3818,"interventions":3819},[90],[597],[599,581],{"trials":3821,"activeCount":101},[],{"trials":3823,"activeCount":101},[],{"trials":3825,"activeCount":101},[],{"intervention":3827,"totalTrials":97,"cells":3828},"Standard of Care",{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3833,"PHASE3":3843,"PHASE4":3845,"NA":3847},{"trials":3830,"activeCount":101},[],{"trials":3832,"activeCount":101},[],{"trials":3834,"activeCount":101},[3835],{"nctId":3836,"briefTitle":3837,"status":170,"phases":3838,"primaryCompletion":822,"completion":822,"start":1179,"enrollment":3839,"conditions":3840,"interventions":3841},"NCT01133119","Use of Local Anesthetic (0.25% Bupivacaine) for Pain Control in Pediatric Cardiac Catheterization",[90],140,[18],[3827,3842],"Standard of Care plus bupivacaine",{"trials":3844,"activeCount":101},[],{"trials":3846,"activeCount":101},[],{"trials":3848,"activeCount":101},[],{"intervention":3842,"totalTrials":97,"cells":3850},{"EARLY_PHASE1":3851,"PHASE1":3853,"PHASE2":3855,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3852,"activeCount":101},[],{"trials":3854,"activeCount":101},[],{"trials":3856,"activeCount":101},[3857],{"nctId":3836,"briefTitle":3837,"status":170,"phases":3858,"primaryCompletion":822,"completion":822,"start":1179,"enrollment":3839,"conditions":3859,"interventions":3860},[90],[18],[3827,3842],{"trials":3862,"activeCount":101},[],{"trials":3864,"activeCount":101},[],{"trials":3866,"activeCount":101},[],{"intervention":3868,"totalTrials":97,"cells":3869},"5 Azacytidine",{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3885,"PHASE3":3887,"PHASE4":3889,"NA":3891},{"trials":3871,"activeCount":101},[],{"trials":3873,"activeCount":101},[3874],{"nctId":3875,"briefTitle":3876,"status":170,"phases":3877,"primaryCompletion":2877,"completion":2650,"start":3878,"enrollment":3879,"conditions":3880,"interventions":3884},"NCT03206021","COZMOS:Phase I\u002FIb Trial of Combined 5'Azacitidine and Carboplatin for Recurrent\u002FRefractory Pediatric Brain\u002FSolid Tumors",[89],"2017-08-01",31,[3881,3882,3883],"Recurrent Childhood CNS Tumor","Ependymoma, Recurrent Childhood","Childhood Solid Tumor",[3868],{"trials":3886,"activeCount":101},[],{"trials":3888,"activeCount":101},[],{"trials":3890,"activeCount":101},[],{"trials":3892,"activeCount":101},[],{"intervention":3894,"totalTrials":97,"cells":3895},"13C5-Calcium-L-Leucovorin",{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3907,"PHASE3":3909,"PHASE4":3911,"NA":3913},{"trials":3897,"activeCount":101},[],{"trials":3899,"activeCount":101},[3900],{"nctId":3901,"briefTitle":3902,"status":170,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":1302,"enrollment":29,"conditions":3905,"interventions":3906},"NCT00941174","Folate Absorption Across the Large Intestine",[89],"2009-03",[15],[3894],{"trials":3908,"activeCount":101},[],{"trials":3910,"activeCount":101},[],{"trials":3912,"activeCount":101},[],{"trials":3914,"activeCount":101},[],{"intervention":3916,"totalTrials":97,"cells":3917},"Vinblastine and Sirolimus",{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3931,"PHASE3":3933,"PHASE4":3935,"NA":3937},{"trials":3919,"activeCount":101},[],{"trials":3921,"activeCount":101},[3922],{"nctId":3923,"briefTitle":3924,"status":170,"phases":3925,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":3397,"conditions":3928,"interventions":3930},"NCT01135563","Study of Vinblastine and Sirolimus in Children With Recurrent\u002FRefractory Solid Tumours Including CNS Tumours",[89],"2012-04","2010-04",[2903,3929],"Central Nervous System Tumors",[3916],{"trials":3932,"activeCount":101},[],{"trials":3934,"activeCount":101},[],{"trials":3936,"activeCount":101},[],{"trials":3938,"activeCount":101},[],{"intervention":3940,"totalTrials":97,"cells":3941},"TIL-TC150",{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3955,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3943,"activeCount":101},[],{"trials":3945,"activeCount":101},[3946],{"nctId":3947,"briefTitle":3948,"status":170,"phases":3949,"primaryCompletion":3950,"completion":3951,"start":3952,"enrollment":218,"conditions":3953,"interventions":3954},"NCT02983695","Cannabinoid Therapy for Pediatric Epilepsy",[89],"2018-08-24","2021-07-20","2017-02-02",[1779],[3940],{"trials":3956,"activeCount":101},[],{"trials":3958,"activeCount":101},[],{"trials":3960,"activeCount":101},[],{"trials":3962,"activeCount":101},[],{"intervention":3964,"totalTrials":97,"cells":3965},"Topotecan Episcleral Plaque",{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":3980,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3967,"activeCount":101},[],{"trials":3969,"activeCount":101},[3970],{"nctId":3971,"briefTitle":3972,"status":170,"phases":3973,"primaryCompletion":3974,"completion":3975,"start":3976,"enrollment":3977,"conditions":3978,"interventions":3979},"NCT04428879","Topotecan Episcleral Plaque for Treatment of Retinoblastoma",[89],"2024-10-01","2024-10-03","2020-06-16",26,[2976],[3964],{"trials":3981,"activeCount":101},[],{"trials":3983,"activeCount":101},[],{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"intervention":3989,"totalTrials":97,"cells":3990},"Rifampin 150 mg, 300 mg capsules and 25 mg\u002FmL oral suspension",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":3992,"activeCount":101},[],{"trials":3994,"activeCount":101},[3995],{"nctId":3996,"briefTitle":3997,"status":607,"phases":3998,"primaryCompletion":3999,"completion":3999,"start":4000,"enrollment":2801,"conditions":4001,"interventions":4003},"NCT03384121","The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH",[89],"2021-12-31","2018-02-22",[4002],"Idiopathic Infantile Hypercalcemia - Mild Form",[3989],{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"intervention":4013,"totalTrials":97,"cells":4014},"Aprepitant Capsule 125 MG",{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4028,"PHASE3":4030,"PHASE4":4032,"NA":4034},{"trials":4016,"activeCount":101},[],{"trials":4018,"activeCount":101},[4019],{"nctId":4020,"briefTitle":4021,"status":170,"phases":4022,"primaryCompletion":4023,"completion":4024,"start":269,"enrollment":1021,"conditions":4025,"interventions":4026},"NCT03245918","Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers",[89],"2017-12-31","2018-01-05",[264],[4013,4027],"Aprepitant oral suspension 20 mg\u002FmL",{"trials":4029,"activeCount":101},[],{"trials":4031,"activeCount":101},[],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"intervention":4027,"totalTrials":97,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4046,"PHASE3":4048,"PHASE4":4050,"NA":4052},{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[4042],{"nctId":4020,"briefTitle":4021,"status":170,"phases":4043,"primaryCompletion":4023,"completion":4024,"start":269,"enrollment":1021,"conditions":4044,"interventions":4045},[89],[264],[4013,4027],{"trials":4047,"activeCount":101},[],{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":101},[],{"intervention":4055,"totalTrials":97,"cells":4056},"Methylphenidate",{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4069,"PHASE3":4071,"PHASE4":4073,"NA":4075},{"trials":4058,"activeCount":101},[],{"trials":4060,"activeCount":101},[4061],{"nctId":4062,"briefTitle":4063,"status":170,"phases":4064,"primaryCompletion":3113,"completion":1242,"start":4065,"enrollment":1077,"conditions":4066,"interventions":4068},"NCT02453698","Stimulant Effects on Brain Activity",[89],"2011-01",[4067],"Healthy Volunteers",[4055],{"trials":4070,"activeCount":101},[],{"trials":4072,"activeCount":101},[],{"trials":4074,"activeCount":101},[],{"trials":4076,"activeCount":101},[],{"intervention":4078,"totalTrials":97,"cells":4079},"Alprostadil 5 MCG",{"EARLY_PHASE1":4080,"PHASE1":4082,"PHASE2":4093,"PHASE3":4095,"PHASE4":4097,"NA":4099},{"trials":4081,"activeCount":101},[],{"trials":4083,"activeCount":101},[4084],{"nctId":4085,"briefTitle":4086,"status":592,"phases":4087,"primaryCompletion":4088,"completion":4089,"start":4090,"enrollment":464,"conditions":4091,"interventions":4092},"NCT04054115","Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow",[89],"2021-02-24","2022-11-09","2019-07-23",[23],[4078],{"trials":4094,"activeCount":101},[],{"trials":4096,"activeCount":101},[],{"trials":4098,"activeCount":101},[],{"trials":4100,"activeCount":101},[],{"intervention":4102,"totalTrials":97,"cells":4103},"Metformin Hydrochloride",{"EARLY_PHASE1":4104,"PHASE1":4106,"PHASE2":4118,"PHASE3":4120,"PHASE4":4122,"NA":4124},{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[4108],{"nctId":4109,"briefTitle":4110,"status":592,"phases":4111,"primaryCompletion":4112,"completion":4112,"start":4113,"enrollment":97,"conditions":4114,"interventions":4117},"NCT05590676","Metformin Treatment in Infants After Perinatal Brain Injury",[89],"2024-02-22","2023-05-02",[4115,4116],"Hypoxic Ischemic Encephalopathy of Newborn","Premature Birth",[4102],{"trials":4119,"activeCount":101},[],{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"intervention":4127,"totalTrials":3550,"cells":4128},"Hypertonic Saline",{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4140,"PHASE3":4149,"PHASE4":4159,"NA":4161},{"trials":4130,"activeCount":101},[],{"trials":4132,"activeCount":101},[4133],{"nctId":4134,"briefTitle":4135,"status":170,"phases":4136,"primaryCompletion":868,"completion":1253,"start":4137,"enrollment":1777,"conditions":4138,"interventions":4139},"NCT00753987","Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis",[89],"2006-03",[20],[4127],{"trials":4141,"activeCount":101},[4142],{"nctId":4143,"briefTitle":4144,"status":170,"phases":4145,"primaryCompletion":1180,"completion":1180,"start":824,"enrollment":4146,"conditions":4147,"interventions":4148},"NCT00721071","Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis",[90],95,[20],[4127],{"trials":4150,"activeCount":101},[4151],{"nctId":4152,"briefTitle":4153,"status":170,"phases":4154,"primaryCompletion":1252,"completion":1252,"start":4155,"enrollment":218,"conditions":4156,"interventions":4157},"NCT00635141","The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis",[91],"2008-03",[20],[4158,4158],"hypertonic saline",{"trials":4160,"activeCount":101},[],{"trials":4162,"activeCount":101},[4163],{"nctId":4164,"briefTitle":4165,"status":170,"phases":4166,"primaryCompletion":4167,"completion":4167,"start":4168,"enrollment":1243,"conditions":4169,"interventions":4170},"NCT00700050","Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways",[],"2014-07-29","2008-04",[20],[4171,4171,4171,4171],"Hypertonic saline",{"intervention":4173,"totalTrials":204,"cells":4174},"Morphine",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4191,"PHASE4":4199,"NA":4201},{"trials":4176,"activeCount":101},[],{"trials":4178,"activeCount":101},[],{"trials":4180,"activeCount":101},[4181],{"nctId":4182,"briefTitle":4183,"status":1133,"phases":4184,"primaryCompletion":4185,"completion":4186,"start":4187,"enrollment":101,"conditions":4188,"interventions":4190},"NCT03035578","Development of a Morphine Pharmacokinetic and Pharmacodynamic Model for the Neonatal Population",[89,90],"2018-06-01","2019-06-01","2017-12-01",[18,4189],"Drug Effect",[4173,4173],{"trials":4192,"activeCount":101},[4193],{"nctId":4194,"briefTitle":4195,"status":170,"phases":4196,"primaryCompletion":2270,"completion":1110,"start":824,"enrollment":2035,"conditions":4197,"interventions":4198},"NCT00737997","Effect of Early Morphine Administration on the Development of Acute Opioid Tolerance During Pediatric Scoliosis Surgery",[91],[1183],[4173],{"trials":4200,"activeCount":101},[],{"trials":4202,"activeCount":101},[4203],{"nctId":4204,"briefTitle":4205,"status":170,"phases":4206,"primaryCompletion":4207,"completion":4207,"start":4208,"enrollment":4209,"conditions":4210,"interventions":4211},"NCT05372133","Split Scripts for Pediatric Supracondylar Fracture Repairs",[93],"2023-08-18","2022-08-11",175,[119],[4173],{"intervention":1091,"totalTrials":145,"cells":4213},{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4220,"PHASE4":4226,"NA":4228},{"trials":4215,"activeCount":101},[],{"trials":4217,"activeCount":101},[],{"trials":4219,"activeCount":101},[],{"trials":4221,"activeCount":101},[4222],{"nctId":1082,"briefTitle":1083,"status":607,"phases":4223,"primaryCompletion":1085,"start":1086,"enrollment":1087,"conditions":4224,"interventions":4225},[91],[18],[1090,1091,1092,1051],{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[4230],{"nctId":4231,"briefTitle":4232,"status":607,"phases":4233,"completion":4234,"start":1434,"enrollment":4235,"conditions":4236,"interventions":4238},"NCT00213213","Using Sugar Water to Relieve Pain in Infants",[93],"2005-07",240,[18,1437,4237],"Diabetes",[1091],{"intervention":4240,"totalTrials":97,"cells":4241},"either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe",{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4246,"PHASE3":4248,"PHASE4":4250,"NA":4252},{"trials":4243,"activeCount":101},[],{"trials":4245,"activeCount":101},[],{"trials":4247,"activeCount":101},[],{"trials":4249,"activeCount":101},[],{"trials":4251,"activeCount":101},[],{"trials":4253,"activeCount":101},[4254],{"nctId":4255,"briefTitle":4256,"status":170,"phases":4257,"primaryCompletion":4258,"completion":4259,"start":4260,"enrollment":4261,"conditions":4262,"interventions":4264},"NCT05543122","Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants",[],"2023-12-23","2024-03-31","2022-03-09",39,[4263],"Breast Feeding",[4240],{"intervention":4266,"totalTrials":97,"cells":4267},"Hyperpolarized 129-xenon gas and Perfluoropropane gas",{"EARLY_PHASE1":4268,"PHASE1":4270,"PHASE2":4272,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4269,"activeCount":101},[],{"trials":4271,"activeCount":101},[],{"trials":4273,"activeCount":101},[],{"trials":4275,"activeCount":101},[],{"trials":4277,"activeCount":101},[],{"trials":4279,"activeCount":101},[4280],{"nctId":4281,"briefTitle":4282,"status":592,"phases":4283,"primaryCompletion":4284,"completion":4284,"start":4285,"enrollment":240,"conditions":4286,"interventions":4287},"NCT04726618","Development of Hardware and Software for Pulmonary Magnetic Resonance Imaging Using Inhaled Tracer Gases",[],"2024-04-09","2022-03-01",[4067],[4266],{"intervention":4289,"totalTrials":97,"cells":4290},"129Xenon gas",{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4295,"PHASE3":4297,"PHASE4":4299,"NA":4301},{"trials":4292,"activeCount":101},[],{"trials":4294,"activeCount":101},[],{"trials":4296,"activeCount":101},[],{"trials":4298,"activeCount":101},[],{"trials":4300,"activeCount":101},[],{"trials":4302,"activeCount":101},[4303],{"nctId":4304,"briefTitle":4305,"status":592,"phases":4306,"primaryCompletion":4307,"completion":4307,"start":4308,"enrollment":29,"conditions":4309,"interventions":4311},"NCT05014516","Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI",[],"2024-03-20","2021-08-05",[4310],"COVID-19 Respiratory Infection",[4289],{"intervention":4313,"totalTrials":97,"cells":4314},"salbutamol",{"EARLY_PHASE1":4315,"PHASE1":4317,"PHASE2":4319,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4316,"activeCount":101},[],{"trials":4318,"activeCount":101},[],{"trials":4320,"activeCount":101},[],{"trials":4322,"activeCount":101},[],{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[4327],{"nctId":4328,"briefTitle":4329,"status":170,"phases":4330,"primaryCompletion":4331,"completion":4331,"start":3506,"enrollment":4332,"conditions":4333,"interventions":4337},"NCT02743663","The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children",[],"2020-12",121,[296,4334,466,4335,4336],"Wheeze","Food Allergy","Virus",[4313],{"intervention":4339,"totalTrials":97,"cells":4340},"Proctofoam-HC®",{"EARLY_PHASE1":4341,"PHASE1":4343,"PHASE2":4345,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4342,"activeCount":101},[],{"trials":4344,"activeCount":101},[],{"trials":4346,"activeCount":101},[],{"trials":4348,"activeCount":101},[],{"trials":4350,"activeCount":101},[],{"trials":4352,"activeCount":101},[4353],{"nctId":4354,"briefTitle":4355,"status":170,"phases":4356,"primaryCompletion":1204,"completion":1860,"start":708,"enrollment":4357,"conditions":4358,"interventions":4360},"NCT00405288","The Safety of Proctofoam-HC in the Third Trimester of Pregnancy",[],408,[4359,28],"Hemorrhoids",[4339],{"intervention":4362,"totalTrials":97,"cells":4363},"Pamidronate Disodium",{"EARLY_PHASE1":4364,"PHASE1":4366,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4365,"activeCount":101},[],{"trials":4367,"activeCount":101},[],{"trials":4369,"activeCount":101},[],{"trials":4371,"activeCount":101},[],{"trials":4373,"activeCount":101},[],{"trials":4375,"activeCount":101},[4376],{"nctId":4377,"briefTitle":4378,"status":592,"phases":4379,"primaryCompletion":1202,"completion":4380,"start":1157,"enrollment":218,"conditions":4381,"interventions":4383},"NCT02007915","The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head",[93],"2013-06",[4382],"Femoral Head Avascular Necrosis",[4362],{"intervention":4385,"totalTrials":97,"cells":4386},"Hypersaline",{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4397},{"trials":4388,"activeCount":101},[],{"trials":4390,"activeCount":101},[],{"trials":4392,"activeCount":101},[],{"trials":4394,"activeCount":101},[],{"trials":4396,"activeCount":101},[],{"trials":4398,"activeCount":101},[4399],{"nctId":4400,"briefTitle":4401,"status":170,"phases":4402,"primaryCompletion":796,"completion":796,"start":1203,"enrollment":1986,"conditions":4403,"interventions":4405},"NCT02453750","Airway Inflammation in Congenital Diaphragmatic Hernia Patients",[93],[4404],"Congenital Diaphragmatic Hernia",[4385,4406],"Bronchodilator Response",{"intervention":4406,"totalTrials":97,"cells":4408},{"EARLY_PHASE1":4409,"PHASE1":4411,"PHASE2":4413,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4410,"activeCount":101},[],{"trials":4412,"activeCount":101},[],{"trials":4414,"activeCount":101},[],{"trials":4416,"activeCount":101},[],{"trials":4418,"activeCount":101},[],{"trials":4420,"activeCount":101},[4421],{"nctId":4400,"briefTitle":4401,"status":170,"phases":4422,"primaryCompletion":796,"completion":796,"start":1203,"enrollment":1986,"conditions":4423,"interventions":4424},[93],[4404],[4385,4406],{"intervention":4426,"totalTrials":97,"cells":4427},"Traditional",{"EARLY_PHASE1":4428,"PHASE1":4430,"PHASE2":4432,"PHASE3":4434,"PHASE4":4436,"NA":4438},{"trials":4429,"activeCount":101},[],{"trials":4431,"activeCount":101},[],{"trials":4433,"activeCount":101},[],{"trials":4435,"activeCount":101},[],{"trials":4437,"activeCount":101},[],{"trials":4439,"activeCount":101},[4440],{"nctId":4441,"briefTitle":4442,"status":170,"phases":4443,"primaryCompletion":4444,"completion":4444,"start":2100,"enrollment":4445,"conditions":4446,"interventions":4447},"NCT01676636","Delivery Vehicles for Prenatal Calcium Supplementation",[],"2013-03",149,[28],[4426,4448,4449,4450],"Chewable","Unflavoured Powder","Flavoured Powder",{"intervention":4448,"totalTrials":97,"cells":4452},{"EARLY_PHASE1":4453,"PHASE1":4455,"PHASE2":4457,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4454,"activeCount":101},[],{"trials":4456,"activeCount":101},[],{"trials":4458,"activeCount":101},[],{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[],{"trials":4464,"activeCount":101},[4465],{"nctId":4441,"briefTitle":4442,"status":170,"phases":4466,"primaryCompletion":4444,"completion":4444,"start":2100,"enrollment":4445,"conditions":4467,"interventions":4468},[],[28],[4426,4448,4449,4450],{"intervention":4449,"totalTrials":97,"cells":4470},{"EARLY_PHASE1":4471,"PHASE1":4473,"PHASE2":4475,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":101},[],{"trials":4476,"activeCount":101},[],{"trials":4478,"activeCount":101},[],{"trials":4480,"activeCount":101},[],{"trials":4482,"activeCount":101},[4483],{"nctId":4441,"briefTitle":4442,"status":170,"phases":4484,"primaryCompletion":4444,"completion":4444,"start":2100,"enrollment":4445,"conditions":4485,"interventions":4486},[],[28],[4426,4448,4449,4450],{"intervention":4450,"totalTrials":97,"cells":4488},{"EARLY_PHASE1":4489,"PHASE1":4491,"PHASE2":4493,"PHASE3":4495,"PHASE4":4497,"NA":4499},{"trials":4490,"activeCount":101},[],{"trials":4492,"activeCount":101},[],{"trials":4494,"activeCount":101},[],{"trials":4496,"activeCount":101},[],{"trials":4498,"activeCount":101},[],{"trials":4500,"activeCount":101},[4501],{"nctId":4441,"briefTitle":4442,"status":170,"phases":4502,"primaryCompletion":4444,"completion":4444,"start":2100,"enrollment":4445,"conditions":4503,"interventions":4504},[],[28],[4426,4448,4449,4450],{"intervention":4506,"totalTrials":97,"cells":4507},"Beta Adrenergic Sweat Test",{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4512,"PHASE3":4514,"PHASE4":4516,"NA":4518},{"trials":4509,"activeCount":101},[],{"trials":4511,"activeCount":101},[],{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":101},[],{"trials":4517,"activeCount":101},[],{"trials":4519,"activeCount":101},[4520],{"nctId":4521,"briefTitle":4522,"status":1133,"phases":4523,"primaryCompletion":4524,"completion":4524,"start":4524,"enrollment":101,"conditions":4525,"interventions":4527},"NCT04274413","CFTR Related Pancreatitis Study",[93],"2021-02-01",[20,4526],"CFTR Gene Dysfunction",[4506],{"intervention":4529,"totalTrials":97,"cells":4530},"Multiple micronutrient supplement",{"EARLY_PHASE1":4531,"PHASE1":4533,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[],{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[],{"trials":4542,"activeCount":101},[4543],{"nctId":4544,"briefTitle":4545,"status":170,"phases":4546,"completion":4547,"start":4548,"enrollment":4549,"conditions":4550,"interventions":4552},"NCT00392418","Flexible Administration of Sprinkles® in Infants and Young Children in Rural Bangladesh.",[93],"2005-03","2004-05",360,[4551],"Anemia",[4529],{"intervention":4554,"totalTrials":97,"cells":4555},"iron supplement, iron drops",{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4560,"PHASE3":4562,"PHASE4":4564,"NA":4566},{"trials":4557,"activeCount":101},[],{"trials":4559,"activeCount":101},[],{"trials":4561,"activeCount":101},[],{"trials":4563,"activeCount":101},[],{"trials":4565,"activeCount":101},[],{"trials":4567,"activeCount":101},[4568],{"nctId":4569,"briefTitle":4570,"status":170,"phases":4571,"completion":1123,"start":4572,"enrollment":4573,"conditions":4574,"interventions":4575},"NCT00213161","Using Iron Supplementation to Decrease Iron Deficiency Anemia in Infants and Young Children in India",[93],"2004-08",425,[4551],[4554],{"intervention":4577,"totalTrials":97,"cells":4578},"Sodium Chloride Inhalation",{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4580,"activeCount":101},[],{"trials":4582,"activeCount":101},[],{"trials":4584,"activeCount":101},[],{"trials":4586,"activeCount":101},[],{"trials":4588,"activeCount":101},[],{"trials":4590,"activeCount":101},[4591],{"nctId":4592,"briefTitle":4593,"status":170,"phases":4594,"primaryCompletion":1582,"completion":4595,"start":1204,"enrollment":4596,"conditions":4597,"interventions":4598},"NCT01095354","Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma",[],"2018-05-23",49,[296],[4577],{"intervention":4600,"totalTrials":97,"cells":4601},"Oxygen gas",{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4606,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4603,"activeCount":101},[],{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":101},[],{"trials":4609,"activeCount":101},[],{"trials":4611,"activeCount":101},[],{"trials":4613,"activeCount":101},[4614],{"nctId":4615,"briefTitle":4616,"status":170,"phases":4617,"primaryCompletion":4618,"completion":4618,"start":4619,"enrollment":1170,"conditions":4620,"interventions":4622},"NCT03771534","Acute Maternal Hyperoxygenation for Fetal Transposition of the Great Arteries (TGA)",[93],"2023-12-31","2018-09-20",[4621],"TGA - Transposition of Great Arteries",[4600],{"intervention":4624,"totalTrials":97,"cells":4625},"Ondansetron Oral Disintegrating",{"EARLY_PHASE1":4626,"PHASE1":4628,"PHASE2":4630,"PHASE3":4632,"PHASE4":4634,"NA":4636},{"trials":4627,"activeCount":101},[],{"trials":4629,"activeCount":101},[],{"trials":4631,"activeCount":101},[],{"trials":4633,"activeCount":101},[],{"trials":4635,"activeCount":101},[],{"trials":4637,"activeCount":101},[4638],{"nctId":4639,"briefTitle":4640,"status":170,"phases":4641,"primaryCompletion":2034,"completion":2034,"start":3752,"conditions":4642,"interventions":4644},"NCT00120744","Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department",[93],[711,666,4643,712],"Diarrhea",[4624],{"intervention":4646,"totalTrials":97,"cells":4647},"15% oxygen",{"EARLY_PHASE1":4648,"PHASE1":4650,"PHASE2":4652,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4649,"activeCount":101},[],{"trials":4651,"activeCount":101},[],{"trials":4653,"activeCount":101},[],{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[4660],{"nctId":4661,"briefTitle":4662,"status":170,"phases":4663,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":4666,"conditions":4667,"interventions":4670},"NCT03312361","Assessing Air Travel Safety in Neuromuscular Dystrophy: Standard Versus Prolonged High Altitude Simulation Tests",[93],"2018-04-01","2016-04-01",23,[4668,4669],"Neuromuscular Diseases","High Altitude Hypoxia",[4646]]